Stress repair mechanism activity explains inflammation and apoptosis

Lewis S. Coleman

Barnes Dental Surgery Center, 2626 S. Mooney Blvd, Visalia, Ca..

DOI: 10.4236/abb.2012.324065                

Abstract

A review of modern evidence using Internet resources has identified the Stress Repair Mechanism (SRM) postulated by Hans Selye in 1951. SRM activity regulates thrombin generation to govern tissue maintenance, tissue repair, hemodynamic physiology, inflammation, and apoptosis. Thrombin utilizes ATP to energize coagulation, capillary hemostasis, chemotaxis, immune activity, mitosis, metabolism, angiogenesis, and the release of chemokines, cytokines, bradykinins, and prostaglandins that enable cell-to-cell communications, promote perfusion, loosen cell connections, and sensitize nociceptors during tissue repair. The orchestration of these diverse activities by the SRM explains the disparate elements of the inflammation syndrome, including dolor (pain), rubor (redness), calor (heat), tumor (swelling), and Functio laesa (loss of function). Inflammation resolves as tissue repair nears completion and declining SRM activity restores thrombin to maintenance levels. As thrombin levels decline below a critical threshold, repair cells undergo apoptosis and clots disintegrate. Apoptosis shrinks granulation tissues to enable wound closure. Apoptosis also facilitates embryological development. Occult systemic SRM hyperactivity due to sepsis, surgery, trauma, chemicals, pain, fear, and emotional memories causes inflammatory effects that manifest as the fever, edema, malignancy, organ disruption, eclampsia, Multi-System Organ Failure (MS-OF), Systemic Inflammatory Response Syndrome (SI-RS), Adult Respiratory Distress Syndrome (ARDS), Disseminated Intravascular Coagulation (DIC) and other pathologies.

Keywords

Selye; Stress; Inflammation; Atherosclerosis; Tissue Repair; Hemodynamic

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Chanson, M.; Derouette, J. P.; Roth, I.; Foglia, B.; Scerri, I.; Dudez, T.; Kwak, B. R., Gap junctional communication in tissue inflammation and repair. Biochim. Biophys. Acta 2005, 1711 (2), 197-207.
[2]	Yehuda, R. M., B, Behavioral Stress Response: Protective and Damaging Effects. Annals ed.; New York Academy of Science: 2005; p 331.
[3]	Fink, S., Beyond Bad: New Ways of Considering the Stress Response. New York Academy of Sciences Magazine 205, 2005, p 2.
[4]	Coleman, L. S., A Stress Repair Mechanism that Maintains Vertebrate Structure during Stress. Cardiovasc Hematol Disord Drug Targets 2010.
[5]	Petrovitch, C. T. In An Approach to the Patient Who May Have a Bleeding Disorder, American Society of Anesthesiologists Annual Meeting, San Francisco, Ca., October 11-15, 20003; American Society of Anesthesiologists: San Francisco, Ca., 2003; p 186.
[6]	Coleman, L. S., Insoluble fibrin may reduce turbulence and bind blood components into clots. Med. Hypotheses 2005, 65 (4), 820-1.
[7]	Coleman, L. S., An Improved Explanation of Atherosclerosis. PLoS Medicine 2005, 2(4):e98.
[8]	Coleman, L. S., Atherosclerosis may be caused by inadequate levels of turbulence and mixing. World J. Surg. 2006, 30 (4), 638-9.
[9]	Coleman, L. S., A capillary hemostasis mechanism regulated by sympathetic tone and activity via factor VIII or von Willebrand's factor may function as a "capillary gate" and may explain angiodysplasia, angioneurotic edema, and variations in systemic vascular resistance. Med. Hypotheses 2005.
[10]	Coleman, L. S., To the Editor: Is von Willebrand Factor a Hormone that Regulates a Coagulation Mechanism? World J. Surg. 2006.
[11]	Coleman, L. S., A hypothesis: Factor VII governs clot formation, tissue repair and apoptosis. Med. Hypotheses 2007.
[12]	Coleman, L. S., A testable hypothesis that may explain the morbidity and mortality caused by surgical stress. Anesth. Analg. 2006, 103 (6), 1589; author reply 1589-90.
[13]	Coleman, L. S., 30 Years Lost in Anesthesia Theory. Cardiovasc Hematol Agents Med Chem 2012.
[14]	Kerr, J. F.; Wyllie, A. H.; Currie, A. R., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 1972, 26 (4), 239-57.
[15]	Itakura, T.; Yamamoto, K.; Tohyama, M.; Shimizu, N., Central dual innervation of arterioles and capillaries in the brain. Stroke 1977, 8 (3), 360-5.
[16]	Si, M. L.; Lee, T. J., Alpha7-nicotinic acetylcholine receptors on cerebral perivascular sympathetic nerves mediate choline-induced nitrergic neurogenic vasodilation. Circ. Res. 2002, 91 (1), 62-9.
[17]	Naldini, A.; Carney, D. H.; Bocci, V.; Klimpel, K. D.; Asuncion, M.; Soares, L. E.; Klimpel, G. R., Thrombin enhances T cell proliferative responses and cytokine production. Cell. Immunol. 1993, 147 (2), 367-77.
[18]	Smith, D. B.; Janmey, P. A.; Herbert, T. J.; Lind, S. E., Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots. J. Lab. Clin. Med. 1987, 110 (2), 189-95.
[19]	Gong, Y.; Xi, G. H.; Keep, R. F.; Hoff, J. T.; Hua, Y., Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. Acta Neurochir Suppl 2005, 95, 389-92.
[20]	Sambrano, G. R.; Weiss, E. J.; Zheng, Y. W.; Huang, W.; Coughlin, S. R., Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001, 413 (6851), 74-8.
[21]	Archiniegas, E.; Neves, C. Y.; Candelle, D.; Cardier, J. E., Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process. DNA Cell Biol. 2004, 23 (12), 815-25.
[22]	Armstrong, M. T.; Lee, D. Y.; Armstrong, P. B., Regulation of proliferation of the fetal myocardium. Dev. Dyn. 2000, 219 (2), 226-36.
[23]	Murakami, K.; Ueno, A.; Yamanouchi, K.; Kondo, T., Thrombin induces GRO alpha/MGSA production in human umbilical vein endothelial cells. Thromb. Res. 1995, 79 (4), 387-94.
[24]	Moser, M.; Patterson, C., Thrombin and vascular development: a sticky subject. Arterioscler. Thromb. Vasc. Biol. 2003, 23 (6), 922-30.
[25]	Luo, W.; Wang, Y.; Reiser, G., Two types of protease-activated receptors (PAR-1 and PAR-2) mediate calcium signaling in rat retinal ganglion cells RGC-5. Brain Res. 2005, 1047 (2), 159-67.
[26]	Mann, K. G.; Brummel, K.; Butenas, S., What is all that thrombin for? J Thromb Haemost 2003, 1 (7), 1504-14.
[27]	Sutherland, C. J.; Schurman, J. R., Complications associated with warfarin prophylaxis in total knee arthroplasty. Clin. Orthop. 1987, (219), 158-62.
[28]	Goldsack, N. R.; Chambers, R. C.; Dabbagh, K.; Laurent, G. J., Thrombin. Int. J. Biochem. Cell Biol. 1998, 30 (6), 641-6.
[29]	Haas, S., [Future potential indications for an oral thrombin inhibitor]. Hamostaseologie 2002, 22 (3), 36-43.
[30]	Hedner, U., General haemostatic agents-fact or fiction? Pathophysiol Haemost Thromb 2002, 32 Suppl 1, 33-6.
[31]	Mahajan, V. B.; Pai, K. S.; Lau, A.; Cunningham, D. D., Creatine kinase, an ATP-generating enzyme, is required for thrombin receptor signaling to the cytoskeleton. Proc. Natl. Acad. Sci. U. S. A. 2000, 97 (22), 12062-7.
[32]	Warkentin, T. E.; Sikov, W. M.; Lillicrap, D. P., Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am. J. Hematol. 1999, 62 (1), 44-8.
[33]	Chinni, C.; de Niese, M. R.; Tew, D. J.; Jenkins, A. L.; Bottomley, S. P.; Mackie, E. J., Thrombin, a survival factor for cultured myoblasts. J. Biol. Chem. 1999, 274 (14), 9169-74.
[34]	Pagel, C. N.; de Niese, M. R.; Abraham, L. A.; Chinni, C.; Song, S. J.; Pike, R. N.; Mackie, E. J., Inhibition of osteoblast apoptosis by thrombin. Bone 2003, 33 (4), 733-43.
[35]	Naldini, A.; Carney, D. H.; Pucci, A.; Carraro, F., Human alpha-thrombin stimulates proliferation of interferon-gamma differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1. J. Cell. Physiol. 2002, 191 (3), 290-7.
[36]	Brass, L. F.; Molino, M., Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Thromb. Haemost. 1997, 78 (1), 234-41.
[37]	Bretschneider, E.; Kaufmann, R.; Braun, M.; Wittpoth, M.; Glusa, E.; Nowak, G.; Schror, K., Evidence for proteinase-activated receptor-2 (PAR-2)-mediated mitogenesis in coronary artery smooth muscle cells. Br. J. Pharmacol. 1999, 126 (8), 1735-40.
[38]	Chalmers, C. J.; Balmanno, K.; Hadfield, K.; Ley, R.; Cook, S. J., Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. Biochem. J. 2003, 375 (Pt 1), 99-109.
[39]	Day, J. R.; Taylor, K. M.; Lidington, E. A.; Mason, J. C.; Haskard, D. O.; Randi, A. M.; Landis, R. C., Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J. Thorac. Cardiovasc. Surg. 2006, 131 (1), 21-7.
[40]	Gorbacheva, L. R.; Storozhevykh, T. P.; Kiseleva, E. V.; Pinelis, V. G.; Strukova, S. M., Proteinase-activated type 1 receptors are involved in the mechanism of protection of rat hippocampal neurons from glutamate toxicity. Bull. Exp. Biol. Med. 2005, 140 (3), 285-8.
[41]	Wang, K. Y.; Chang, F. H.; Jeng, J. H.; Hou, L. T.; Chen, K. C.; Kuo, M. Y., Expression of functional type 1 protease-activated thrombin receptors by mouse primary palatal mesenchymal cells in vitro. Arch. Oral Biol. 2000, 45 (10), 819-25.
[42]	Wang, H.; Reiser, G., Thrombin signaling in the brain: the role of protease-activated receptors. Biol. Chem. 2003, 384 (2), 193-202.
[43]	Song, S. J.; Pagel, C. N.; Campbell, T. M.; Pike, R. N.; Mackie, E. J., The role of protease-activated receptor-1 in bone healing. Am. J. Pathol. 2005, 166 (3), 857-68.
[44]	Kaushal, V.; Kaushal, G. P.; Melkaveri, S. N.; Mehta, P., Thalidomide protects endothelial cells from doxorubi-cin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004, 2 (2), 327-34.
[45]	Zania, P.; Kritikou, S.; Flordellis, C. S.; Maragoudakis, M. E.; Tsopanoglou, N. E., Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1 (PAR-1): Association with endothelial cell growth suppression and induction of apoptosis. J. Pharmacol. Exp. Ther. 2006.
[46]	Fuentes, A.; Rojas, A.; Porter, K. B.; Saviello, G.; O'Brien, W. F., The effect of magnesium sulfate on bleeding time in pregnancy. Am. J. Obstet. Gynecol. 1995, 173 (4), 1246-9.
[47]	Garcia, J. G.; Pavalko, F. M.; Patterson, C. E., Vascular endothelial cell activation and permeability responses to thrombin. Blood Coagul. Fibrinolysis 1995, 6 (7), 609-26.
[48]	Jeng, J. H.; Chan, C. P.; Wu, H. L.; Ho, Y. S.; Lee, J. J.; Liao, C. H.; Chang, Y. K.; Chang, H. H.; Chen, Y. J.; Perng, P. J.; Chang, M. C., Protease-activated receptor-1-induced calcium signaling in gingival fibroblasts is mediated by sarcoplasmic reticulum calcium release and extracellular calcium influx. Cell. Signal. 2004, 16 (6), 731-40.
[49]	James, M. F.; Roche, A. M., Dose-response relationship between plasma ionized calcium concentration and thrombelastography. J. Cardiothorac. Vasc. Anesth. 2004, 18 (5), 581-6.
[50]	Shapiro, M. J.; Mistry, B., Calcium regulation and nonprotective properties of calcium in surgical ischemia. New Horiz. 1996, 4 (1), 134-8.
[51]	Bobe, R.; Yin, X.; Roussanne, M. C.; Stepien, O.; Polidano, E.; Faverdin, C.; Marche, P., Evidence for ERK1/2 activation by thrombin that is independent of EGFR transactivation. Am J Physiol Heart Circ Physiol 2003, 285 (2), H745-54.
[52]	Brass, E. P.; Forman, W. B.; Edwards, R. V.; Lindan, O., Fibrin formation: effect of calcium ions. Blood 1978, 52 (4), 654-8.
[53]	Brostrom, M. A.; Pan, Z.; Meiners, S.; Drumm, C.; Ahmed, I.; Brostrom, C. O., Ca2+ dynamics of thrombin-stimulated rat heart-derived embryonic myocytes: relationship to protein synthesis and cell growth. Int. J. Biochem. Cell Biol. 2003, 35 (11), 1573-87.
[54]	Butenas, S.; Brummel, K. E.; Paradis, S. G.; Mann, K. G., Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler. Thromb. Vasc. Biol. 2003, 23 (1), 123-9.
[55]	Davies, M. S.; Flannery, M. C.; McCollum, C. N., Calcium alginate as haemostatic swabs in hip fracture surgery. J. R. Coll. Surg. Edinb. 1997, 42 (1), 31-2.
[56]	Gurrieri, M. A., [Thrombin-fibrinogen interaction: release of fibrinopeptides and the effects of ATP]. Medicina (Firenze) 1990, 10 (1), 51-2.
[57]	Murdoch, I. A.; Qureshi, S. A.; Huggon, I. C., Perioperative haemodynamic effects of an intravenous infusion of calcium chloride in children following cardiac surgery. Acta Paediatr. 1994, 83 (6), 658-61.
[58]	Sakariassen, K. S.; Ottenhof-Rovers, M.; Sixma, J. J., Factor VIIIvon Willebrand factor requires calcium for facilitation of platelet adherence. Blood 1984, 63 (5), 996-103.
[59]	Sakata, Y.; Aoki, N., Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J. Clin. Invest. 1980, 65 (2), 290-7.
[60]	von Brecht, J. H.; Flanigan, M. J.; Freeman, R. M.; Lim, V. S., Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am. J. Kidney Dis. 1986, 8 (3), 196-201.
[61]	Zuccala, G.; Pahor, M.; Landi, F.; Gasparini, G.; Pagano, F.; Carbonin, P.; Cocchi, A., Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: observational study. BMJ 1997, 314 (7081), 643-4.
[62]	Zuccala, G.; Pedone, C.; Cocchi, A.; Pahor, M.; Carosella, L.; Carbonin, P.; Bernabei, R., Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study. Gruppo Italiano di Farmacoepidemiologia nell'Anziano (GIFA) investigators. Clin. Pharmacol. Ther. 2000, 67 (3), 314-22.
[63]	Barbagallo, M.; Dominguez, L. J.; Resnick, L. M., Magnesium metabolism in hypertension and type 2 diabetes mellitus. Am. J. Ther. 2007, 14 (4), 375-85.
[64]	Baker, S. B.; Worthley, L. I., The essentials of calcium, magnesium and phosphate metabolism: part II. Disorders. Crit Care Resusc 2002, 4 (4), 307-15.
[65]	Baker, S. B.; Worthley, L. I., The essentials of calcium, magnesium and phosphate metabolism: part I. Physiology. Crit Care Resusc 2002, 4 (4), 301-6.
[66]	James, M. F.; Cronje, L., Pheochromocytoma crisis: the use of magnesium sulfate. Anesth. Analg. 2004, 99 (3), 680-6, table of contents.
[67]	Dedhia, H. V.; Banks, D. E., Pulmonary response to hyperoxia: effects of magnesium. Environ. Health Perspect. 1994, 102 Suppl 10, 101-5.
[68]	Elsharnouby, N. M.; Elsharnouby, M. M., Magnesium sulphate as a technique of hypotensive anaesthesia. Br. J. Anaesth. 2006, 96 (6), 727-31.
[69]	Elin, R. J., Magnesium metabolism in health and disease. Dis. Mon. 1988, 34 (4), 161-218.
[70]	Erodi, A., [Magnesium-an anticoagulant physiological electrolyte]. Med. Klin. 1973, 68 (7), 216-9.
[71]	Fehlinger, R.; Mielke, U.; Fauk, D.; Seidel, K., Rheographic indications for reduced cerebral vasoconstriction after oral magnesium medication in tetanic patients, a double-blind, placebo-controlled trial. Magnesium 1986, 5 (2), 60-5.
[72]	Galland, L., Magnesium, stress and neuropsychiatric disorders. Magnes. Trace Elem. 1991, 10 (2-4), 287-301.
[73]	Kondo, H.; Kobayashi, E.; Itani, T.; Tatsumi, N.; Tsuda, I., Hematology tests of blood anticoagulated with magne-sium sulphate. Southeast Asian J. Trop. Med. Public Health 2002, 33 Suppl 2, 6-9.
[74]	Menzel, R.; Pusch, H.; Ratzmann, G. W.; Besch, W.; Forster, F.; Albrecht, G.; Ruhnke, R., Serum magnesium in insulindependent diabetics and healthy subjects in relation to insulin secretion and glycemia during glucose-glucagon test. Exp. Clin. Endocrinol. 1985, 85 (1), 81-8.
[75]	Mussoni, L.; Sironi, L.; Tedeschi, L.; Calvio, A. M.; Colli, S.; Tremoli, E., Magnesium inhibits arterial thrombi after vascular injury in rat: in vivo impairment of coagulation. Thromb. Haemost. 2001, 86 (5), 1292-5.
[76]	Rukshin, V.; Shah, P. K.; Cercek, B.; Finkelstein, A.; Tsang, V.; Kaul, S., Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. Circulation 2002, 105 (16), 1970-5.
[77]	Scheibe, F.; Haupt, H.; Vlastos, G. A., Preventive magnesium supplement reduces ischemia-induced hearing loss and blood viscosity in the guinea pig. Eur. Arch. Otorhinolaryngol. 2000, 257 (7), 355-61.
[78]	Seelig, M. S., Increased need for magnesium with the use of combined oestrogen and calcium for osteoporosis treatment. Magnes. Res. 1990, 3 (3), 197-215.
[79]	Karp, J. M.; Tanaka, T. S.; Zohar, R.; Sodek, J.; Shoichet, M. S.; Davies, J. E.; Stanford, W. L., Thrombin mediated migration of osteogenic cells. Bone 2005, 37 (3), 337-48.
[80]	Sabri, A.; Muske, G.; Zhang, H.; Pak, E.; Darrow, A.; Andrade-Gordon, P.; Steinberg, S. F., Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ. Res. 2000, 86 (10), 1054-61.
[81]	Tantivejkul, K.; Loberg, R. D.; Mawocha, S. C.; Day, L. L.; John, L. S.; Pienta, B. A.; Rubin, M. A.; Pienta, K. J., PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J. Cell. Biochem. 2005, 96 (3), 641-52.
[82]	Fenton, J. W., 2nd; Ofosu, F. A.; Brezniak, D. V.; Hassouna, H. I., Thrombin and antithrombotics. Semin. Thromb. Hemost. 1998, 24 (2), 87-91.
[83]	Stewart, A. J.; Penman, I. D.; Cook, M. K.; Ludlam, C. A., Warfarin-induced skin necrosis. Postgrad. Med. J. 1999, 75 (882), 233-5.
[84]	Brummel, K. E.; Paradis, S. G.; Butenas, S.; Mann, K. G., Thrombin functions during tissue factor-induced blood coagulation. Blood 2002, 100 (1), 148-52.
[85]	Hong, S. L.; Levine, L., Stimulation of prostaglandin synthesis by bradykinin and thrombin and their mechanisms of action on MC5-5 fibroblasts. J. Biol. Chem. 1976, 251 (18), 5814-6.
[86]	Pohl, J.; Bruhn, H. D.; Christophers, E., Thrombin and fibrin-induced growth of fibroblasts: role in wound repair and thrombus organization. Klin. Wochenschr. 1979, 57 (6), 273-7.
[87]	Wang, H.; Reiser, G., The role of the Ca2+-sensitive tyrosine kinase Pyk2 and Src in thrombin signalling in rat astrocytes. J. Neurochem. 2003, 84 (6), 1349-57.
[88]	Imamura, T., [Tissue factor expression at the site of inflammation: a cross-talk between inflammation and the blood coagulation system]. Rinsho Byori. 2004, 52 (4), 342-9.
[89]	Glembotski, C. C.; Irons, C. E.; Krown, K. A.; Murray, S. F.; Sprenkle, A. B.; Sei, C. A., Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J. Biol. Chem. 1993, 268 (27), 20646-52.
[90]	Okada, M.; Suzuki, K.; Takada, K.; Nakashima, M.; Nakanishi, T.; Shinohara, T., Detection of up-regulated genes in thrombin-stimulated human umbilical vein endothelial cells. Thromb. Res. 2005.
[91]	Rothman, A.; Wolner, B.; Button, D.; Taylor, P., Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells. J. Biol. Chem. 1994, 269 (9), 6399-404.
[92]	Tsopanoglou, N. E.; Maragoudakis, M. E., On the mechanism of thrombin-induced angiogenesis: inhibition of attachment of endothelial cells on basement membrane components. Angiogenesis 1998, 1 (2), 192-200.
[93]	Hornstra, G.; Hemker, H. C., Clot-promoting effect of platelet-vessel wall interaction: influence of dietary fats and relation to arterial thrombus formation in rats. Haemostasis 1979, 8 (3-5), 211-26.
[94]	Hornstra, G., Platelet-vessel wall interaction: role of blood clotting. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1981, 294 (1072), 355-71.
[95]	Henriksen, R. A.; Samokhin, G. P.; Tracy, P. B., Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor. Arterioscler. Thromb. Vasc. Biol. 1997, 17 (12), 3519-26.
[96]	Tate, B. F.; Rittenhouse, S. E., Thrombin activation of human platelets causes tyrosine phosphorylation of PLC-gamma 2. Biochim. Biophys. Acta 1993, 1178 (3), 281-5.
[97]	Asero, R.; Tedeschi, A.; Riboldi, P.; Cugno, M., Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J. Allergy Clin. Immunol. 2006, 117 (5), 1113-7.
[98]	Naldini, A.; Morena, E.; Filippi, I.; Pucci, A.; Bucci, M.; Cirino, G.; Carraro, F., Thrombin inhibits IFN-gamma production in human peripheral blood mononuclear cells by promoting a Th2 profile. J. Interferon Cytokine Res. 2006, 26 (11), 793-9.
[99]	Naldini, A.; Bernini, C.; Pucci, A.; Carraro, F., Thrombin-mediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes. J. Leukoc. Biol. 2005, 78 (3), 736-44.
[100]	Naldini, A.; Carraro, F.; Baldari, C. T.; Paccani, S. R.; Bernini, C.; Keherly, M. J.; Carney, D. H., The thrombin peptide, TP508, enhances cytokine release and activates signaling events. Peptides 2004, 25 (11), 1917-26.
[101]	Naldini, A.; Aarden, L.; Pucci, A.; Bernini, C.; Carraro, F., Inhibition of interleukin-12 expression by alpha-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses. Br. J. Pharmacol. 2003, 140 (5), 980-6.
[102]	Naldini, A.; Pucci, A.; Carney, D. H.; Fanetti, G.; Carraro, F., Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1. Cytokine 2002, 20 (5), 191-9.
[103]	Naldini, A.; Carney, D. H.; Pucci, A.; Pasquali, A.; Carraro, F., Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen. Pharmacol. 2000, 35 (5), 255-9.
[104]	Naldini, A.; Sower, L.; Bocci, V.; Meyers, B.; Carney, D. H., Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. J. Cell. Physiol. 1998, 177 (1), 76-84.
[105]	Ben Amor, N.; Pariente, J. A.; Salido, G. M.; Bartegi, A.; Rosado, J. A., Caspases 3 and 9 are translocated to the cytoskeleton and activated by thrombin in human platelets. Evidence for the involvement of PKC and the actin filament polymerization. Cell. Signal. 2005.
[106]	Ueno, A.; Murakami, K.; Yamanouchi, K.; Watanabe, M.; Kondo, T., Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immu-nology 1996, 88 (1), 76-81.
[107]	Hua, Y.; Keep, R. F.; Schallert, T.; Hoff, J. T.; Xi, G., A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. Acta Neurochir Suppl 2003, 86, 503-6.
[108]	Howell, D. C.; Goldsack, N. R.; Marshall, R. P.; McAnulty, R. J.; Starke, R.; Purdy, G.; Laurent, G. J.; Chambers, R. C., Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 2001, 159 (4), 1383-95.
[109]	Howells, G. L.; Macey, M.; Curtis, M. A.; Stone, S. R., Peripheral blood lymphocytes express the platelet-type thrombin receptor. Br. J. Haematol. 1993, 84 (1), 156-60.
[110]	Tordai, A.; Fenton, J. W., 2nd; Andersen, T.; Gelfand, E. W., Functional thrombin receptors on human T lymphoblastoid cells. J. Immunol. 1993, 150 (11), 4876-86.
[111]	Naldini, A.; Carney, D. H., Thrombin modulation of natural killer activity in human peripheral lymphocytes. Cell. Immunol. 1996, 172 (1), 35-42.
[112]	Huang, Y. Q.; Li, J. J.; Karpatkin, S., Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J. Biol. Chem. 2000, 275 (9), 6462-8.
[113]	Kuznik, B. I.; Malezhik, L. P.; Al'fonov, V. V.; Mamedov Ia, Z., [Effect of thrombin on macrophage and lymphocyte functional activity]. Biull. Eksp. Biol. Med. 1985, 99 (5), 597-8.
[114]	Tran, T.; Stewart, A. G., Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle. Br. J. Pharmacol. 2003, 138 (5), 865-75.
[115]	Vlahos, R.; Lee, K. S.; Guida, E.; Fernandes, D. J.; Wilson, J. W.; Stewart, A. G., Differential inhibition of thrombin- and EGF-stimulated human cultured airway smooth muscle proliferation by glucocorticoids. Pulm. Pharmacol. Ther. 2003, 16 (3), 171-80.
[116]	Laudes, I. J.; Chu, J. C.; Sikranth, S.; Huber-Lang, M.; Guo, R. F.; Riedemann, N.; Sarma, J. V.; Schmaier, A. H.; Ward, P. A., Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 2002, 160 (5), 1867-75.
[117]	Holm, B.; Nilsen, D. W.; Kierulf, P.; Godal, H. C., Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb. Res. 1985, 37 (1), 165-76.
[118]	Bouma, B. N.; Mosnier, L. O., Thrombin activatable fibrinolysis inhibitor (TAFI)-how does thrombin regulate fibrinolysis? Ann. Med. 2006, 38 (6), 378-88.
[119]	Brass, E. P.; Forman, W. B.; Edwards, R. V.; Lindan, O., Fibrin formation: the role of the fibrinogen-fibrin monomer complex. Thromb. Haemost. 1976, 36 (1), 37-48.
[120]	Brummel, K. E.; Butenas, S.; Mann, K. G., An integrated study of fibrinogen during blood coagulation. J. Biol. Chem. 1999, 274 (32), 22862-70.
[121]	Butenas, S.; Mann, K. G., Blood coagulation. Biochemistry (Mosc). 2002, 67 (1), 3-12.
[122]	Juhan-Vague, I.; Hans, M., [From fibrinogen to fibrin and its dissolution]. Bull. Acad. Natl. Med. 2003, 187 (1), 69-82; discussion 83-4.
[123]	Mosesson, M. W., Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005, 3 (8), 1894-904.
[124]	Malik, A. B., Role of fibrin-neutrophil interactions in lung vascular injury. Prog. Clin. Biol. Res. 1987, 236A, 33-42.
[125]	Weisel, J. W., Fibrinogen and fibrin. Adv. Protein Chem. 2005, 70, 247-99.
[126]	Stasko, J.; Hudecek, J.; Kubisz, P., [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis]. Vnitr. Lek. 2004, 50 (1), 36-44.
[127]	Castellino, F. J., Recent Advances in the Chemistry of Fibrinolytic system. Chem. Rev. 1981, 81, 431-446.
[128]	Castoldi, E.; Rosing, J., Factor V Leiden: a disorder of factor V anticoagulant function. Curr. Opin. Hematol. 2004, 11 (3), 176-81.
[129]	Walsh, P. N.; Ahmad, S. S., Proteases in blood clotting. Essays Biochem. 2002, 38, 95-111.
[130]	Augustin, H. G.; Braun, K.; Telemenakis, I.; Modlich, U.; Kuhn, W., Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am. J. Pathol. 1995, 147 (2), 339-51.
[131]	Birkenbach, M.; Josefsen, K.; Yalamanchili, R.; Lenoir, G.; Kieff, E., Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J. Virol. 1993, 67 (4), 2209-20.
[132]	Suo, Z.; Wu, M.; Citron, B. A.; Gao, C.; Festoff, B. W., Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation. J. Biol. Chem. 2003, 278 (33), 31177-83.
[133]	Zain, J.; Huang, Y. Q.; Feng, X.; Nierodzik, M. L.; Li, J. J.; Karpatkin, S., Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000, 95 (10), 3133-8.
[134]	Tsopanoglou, N. E.; Maragoudakis, M. E., Role of thrombin in angiogenesis and tumor progression. Semin. Thromb. Hemost. 2004, 30 (1), 63-9.
[135]	Choi, S. H.; Lee da, Y.; Ryu, J. K.; Kim, J.; Joe, E. H.; Jin, B. K., Thrombin induces nigral dopaminergic neurodegeneration in vivo by altering expression of death-related proteins. Neurobiol. Dis. 2003, 14 (2), 181-93.
[136]	Turgeon, V. L.; Lloyd, E. D.; Wang, S.; Festoff, B. W.; Houenou, L. J., Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. J. Neurosci. 1998, 18 (17), 6882-91.
[137]	Uprichard, J.; Perry, D. J., Factor X deficiency. Blood Rev. 2002, 16 (2), 97-110.
[138]	Schiller, H.; Bartscht, T.; Arlt, A.; Zahn, M. O.; Seifert, A.; Bruhn, T.; Bruhn, H. D.; Gieseler, F., Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro. Int. J. Clin. Pharmacol. Ther. 2002, 40 (8), 329-35.
[139]	Idell, S., Adult respiratory distress syndrome: do selective anticoagulants help? Am J Respir Med 2002, 1 (6), 383-91.
[140]	Bredbacka, S.; Edner, G., Soluble fibrin and D-dimer as detectors of hypercoagulability in patients with isolated brain trauma. J. Neurosurg. Anesthesiol. 1994, 6 (2), 75-82.
[141]	Bredbacka, S.; Blomback, M.; Wiman, B., Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am. J. Hematol. 1994, 46 (4), 289-94.
[142]	Lip, G. Y.; Blann, A. D.; Zarifis, J.; Beevers, M.; Lip, P. L.; Beevers, D. G., Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J. Hypertens. 1995, 13 (12 Pt 2), 1674-8.
[143]	Plendl, H.; Caliebe, A.; Grote, W., [Molecular variants of fibrinogen]. Hamostaseologie 2002, 22 (2), 36-41.
[144]	Idell, S., Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit. Care Med. 2002, 30 (5 Suppl), S274-80.
[145]	Gartner, H. V., [Nephropathy in pregnancy-an endothelial lesion?]. Zentralbl. Gynakol. 1994, 116 (3), 123-37.
[146]	Kawada, H.; Katsura, H.; Kamimura, M.; Toyoda, E.; Kudo, K., [Coagulation activity in the airways of asthmatic patients]. Nihon Kokyuki Gakkai Zasshi 2003, 41 (9), 620-5.
[147]	Widdicombe, J. G., Asthma. Tracheobronchial vasculature. Br. Med. Bull. 1992, 48 (1), 108-19.
[148]	Fan, J.; Kapus, A.; Li, Y. H.; Rizoli, S.; Marshall, J. C.; Rotstein, O. D., Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am. J. Respir. Cell Mol. Biol. 2000, 22 (4), 412-21.
[149]	Akassoglou, K.; Akpinar, P.; Murray, S.; Strickland, S., Fibrin is a regulator of Schwann cell migration after sciatic nerve injury in mice. Neurosci. Lett. 2003, 338 (3), 185-8.
[150]	Akassoglou, K.; Yu, W. M.; Akpinar, P.; Strickland, S., Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron 2002, 33 (6), 861-75.
[151]	Akassoglou, K.; Strickland, S., Nervous system pathology: the fibrin perspective. Biol. Chem. 2002, 383 (1), 37-45.
[152]	Akassoglou, K.; Kombrinck, K. W.; Degen, J. L.; Strickland, S., Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J. Cell Biol. 2000, 149 (5), 1157-66.
[153]	Bredbacka, S.; Blomback, M.; Hagnevik, K.; Irestedt, L.; Raabe, N., Per- and postoperative changes in coagulation and fibrinolytic variables during abdominal hysterectomy under epidural or general anaesthesia. Acta Anaesthesiol. Scand. 1986, 30 (3), 204-10.
[154]	Fairley, J. K.; Owen, J. E.; Birch, D. F., Protein composition of urinary casts from healthy subjects and patients with glomerulonephritis. Br. Med. J. (Clin. Res. Ed). 1983, 287 (6408), 1838-40.
[155]	Ventura, J. E.; Villa, M.; Mizraji, R.; Ferreiros, R., Acute renal failure in pregnancy. Ren. Fail. 1997, 19 (2), 217-20.
[156]	Rath, W.; Faridi, A.; Dudenhausen, J. W., HELLP syndrome. J. Perinat. Med. 2000, 28 (4), 249-60.
[157]	Tighe, D.; Moss, R.; Boghossian, S.; Heath, M. F.; Chessum, B.; Bennett, E. D., Multi-organ damage resulting from experimental faecal peritonitis. Clin Sci (Lond) 1989, 76 (3), 269-76.
[158]	Rodriguez-Inigo, E.; Bartolome, J.; Quiroga, J. A.; Hedner, U.; Suarez, A.; Tomas, J. F.; Manzarbeitia, F.; Arocena, C.; Manzano, M. L.; Oliva, H.; Carreno, V., Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul. Fibrinolysis 2001, 12 (3), 193-9.
[159]	Fiorucci, S.; Antonelli, E.; Distrutti, E.; Severino, B.; Fiorentina, R.; Baldoni, M.; Caliendo, G.; Santagada, V.; Morelli, A.; Cirino, G., PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004, 39 (2), 365-75.
[160]	Schoots, I. G.; Levi, M.; van Vliet, A. K.; Declerck, P. J.; Maas, A. M.; van Gulik, T. M., Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. Thromb. Haemost. 2004, 91 (3), 497-505.
[161]	Kawasaki, J.; Katori, N.; Kodaka, M.; Miyao, H.; Tanaka, K. A., Electron microscopic evaluations of clot morphology during thrombelastography. Anesth. Analg. 2004, 99 (5), 1440-4; table of contents.
[162]	Dargaud, Y.; Beguin, S.; Lienhart, A.; Al Dieri, R.; Trzeciak, C.; Bordet, J. C.; Hemker, H. C.; Negrier, C., Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb. Haemost. 2005, 93 (3), 475-80.
[163]	Dufner, G. S.; Marbet, G. A., [Factor XIII in man: a review]. Hamostaseologie 2002, 22 (1), 11-9.
[164]	Nielsen, V. G.; Gurley, W. Q., Jr.; Burch, T. M., The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth. Analg. 2004, 99 (1), 120-3.
[165]	Goudemand, M., [Plasma fibronectin]. Rev. Fr. Transfus. Immunohematol. 1983, 26 (3), 279-98.
[166]	He, S.; Blomback, M.; Jacobsson Ekman, G.; Hedner, U., The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003, 1 (6), 1215-9.
[167]	McIntosh, J. H.; Owens, D.; Lee, C. A.; Raut, S.; Barrowcliffe, T. W., A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 2003, 1 (5), 1005-11.
[168]	Vehar, G. A.; Davie, E. W., Formation of a serine enzyme in the presence of bovine factor VIII (antihemophilic factor) and thrombin. Science 1977, 197 (4301), 374-6.
[169]	Wettstein, P.; Haeberli, A.; Stutz, M.; Rohner, M.; Corbetta, C.; Gabi, K.; Schnider, T.; Korte, W. j., Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth. Analg. 2004, 99 (5), 1564-9; table of contents.
[170]	Wilmer, M.; Schroder, V.; Kohler, H. P., [Methods for the determination of factor XIII/XIIIa]. Hamostaseologie 2002, 22 (1), 32-42.
[171]	Holemans, R., Enhancement of Fibrinolysis in the Dog by Injection of Vasoactive Drugs. Am. J. Physiol. 1965, 208, 511-20.
[172]	Tamaki, T.; Aoki, N., Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim. Biophys. Acta 1981, 661 (2), 280-6.
[173]	Willert, H. G.; Horrig, C.; Ewald, W.; Scharrer, I., Orthopaedic surgery in hemophilic patients. Arch. Orthop. Trauma Surg. 1983, 101 (2), 121-32.
[174]	Markakis, P.; Papajoannou, N.; Kambouruglou, G., [Fractures in hemophilia patients]. Unfallchirurgie 1984, 10 (4), 173-6.
[175]	Roberts, J. M.; Taylor, R. N.; Musci, T. J.; Rodgers, G. M.; Hubel, C. A.; McLaughlin, M. K., Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 1989, 161 (5), 1200-4.
[176]	Malyszko, J.; Suchowierska, E.; Malyszko, J. S.; Mysliwiec, M., A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Perit. Dial. Int. 2002, 22 (5), 582-92.
[177]	Antovic, J. P.; Antovic, A.; He, S.; Tengborn, L.; Blomback, M., Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII. Haemophilia 2002, 8 (6), 781-6.
[178]	Lisman, T.; Bijsterveld, N. R.; Adelmeijer, J.; Meijers, J. C.; Levi, M.; Nieuwenhuis, H. K.; De Groot, P. G., Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003, 1 (11), 2368-73.
[179]	Malyszko, J.; Malyszko, J. S.; Hryszko, T.; Mysliwiec, M., Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients. Transplant. Proc. 2006, 38 (1), 105-7.
[180]	Grunewald, M.; Siegemund, A.; Grunewald, A.; Konegan, A.; Koksch, M.; Griesshammer, M., Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Hae-mophilia 2002, 8 (6), 768-75.
[181]	Setian, N.; Tanaka, C. M.; Damiani, D.; Dichtchekenian, V.; Carneiro, J. D.; D'Amico, E. A., Hypopituitarism, deficiency of factors V and VIII and von Willebrand factor: an uncommon association. J. Pediatr. Endocrinol. Metab. 2002, 15 (3), 331-3.
[182]	Grunewald, M.; Siegemund, A.; Grunewald, A.; Konegen, A.; Koksch, M.; Griesshammer, M., Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect. Platelets 2002, 13 (8), 451-8.
[183]	Koumbarelis, E.; Rosendaal, F. R.; Gialeraki, A.; Karafoulidou, A.; Noteboom, W. M.; Loizou, C.; Panayotopoulou, C.; Markakis, C.; Mandalaki, T., Epidemiology of haemophilia in Greece: an overview. Thromb. Haemost. 1994, 72 (6), 808-13.
[184]	Cheras, P. A.; Whitaker, A. N.; Blackwell, E. A.; Sinton, T. J.; Chapman, M. D.; Peacock, K. A., Hypercoagulability and hypofibrinolysis in primary osteoarthritis. Clin. Orthop. 1997, (334), 57-67.
[185]	Rosendaal, F. R.; Briet, E.; Stibbe, J.; van Herpen, G.; Leuven, J. A.; Hofman, A.; Vandenbroucke, J. P., Haemophilia protects against ischaemic heart disease: a study of risk factors. Br. J. Haematol. 1990, 75 (4), 525-30.
[186]	Zhang, Z. G.; Chopp, M.; Goussev, A.; Lu, D.; Morris, D.; Tsang, W.; Powers, C.; Ho, K. L., Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J. Neurosci. 1999, 19 (24), 10898-907.
[187]	Zlokovic, B. V.; Wang, L.; Sun, N.; Haffke, S.; Verrall, S.; Seeds, N. W.; Fisher, M. J.; Schreiber, S. S., Expression of tissue plasminogen activator in cerebral capillaries: possible fibrinolytic function of the blood-brain barrier. Neurosurgery 1995, 37 (5), 955-61.
[188]	Tamaki, T.; Aoki, N., Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J. Biol. Chem. 1982, 257 (24), 14767-72.
[189]	O'Donnell, J.; Mumford, A. D.; Manning, R. A.; Laffan, M., Elevation of FVIII: C in venous thromboem-bolism is persistent and independent of the acute phase response. Thromb. Haemost. 2000, 83 (1), 10-3.
[190]	O'Donnell, J.; Mumford, A. D.; Manning, R. A.; Laffan, M. A., Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br. J. Haematol. 2001, 115 (3), 687-91.
[191]	Gutstein, W. H., The central nervous system and atherogenesis: endothelial injury. Atherosclerosis 1988, 70 (1-2), 145-54.
[192]	Lip, G. Y.; Blann, A. D.; Farooqi, I. S.; Zarifis, J.; Sagar, G.; Beevers, D. G., Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul. Fibrinolysis 2002, 13 (4), 339-47.
[193]	Toh, C. H.; Dennis, M., Current clinical practice. DIC 2002: a review of disseminated intravascular coagulation. Hematology 2003, 8 (2), 65-71.
[194]	Tran, T. H.; Lammle, B.; Duckert, F., Factor VIII (procoagulant activity VIII:C, and antigen VIII:CAg, related antigen VIIIR:Ag and ristocetin cofactor VIIIR:Cof) in intensive care patients with clinically suspected disseminated intravascular coagulation (DIC). Am. J. Clin. Pathol. 1984, 82 (5), 565-72.
[195]	Wu, K. C.; Zerhouni, E. A.; Judd, R. M.; Lugo-Olivieri, C. H.; Barouch, L. A.; Schulman, S. P.; Blumenthal, R. S.; Lima, J. A., Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998, 97 (8), 765-72.
[196]	Jaeger, B. R.; Labarrere, C. A., [Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?]. Herz 2003, 28 (6), 530-8.
[197]	Zerbino, D. D.; Lukasevich, L. L., [Syndrome of disseminated intravascular coagulation as the principal morphologic manifestation of shock]. Arkh. Patol. 1983, 45 (12), 13-20.
[198]	Zerbino, D. D.; Lukasevich, L. L., [Disseminated intravascular coagulation syndrome: morphological criteria]. Arkh. Patol. 1982, 44 (7), 29-35.
[199]	Kent, K. M.; Epstein, S. E., Neural basis for the genesis and control of arrhythmias associated with myocardial infarction. Cardiology 1976, 61 (1), 61-74.
[200]	Osterud, B.; Bjorklid, E., The tissue factor pathway in disseminated intravascular coagulation. Semin. Thromb. Hemost. 2001, 27 (6), 605-17.
[201]	Taylor, F. B., Jr.; Chang, A.; Esmon, C. T.; D'Angelo, A.; Vigano-D'Angelo, S.; Blick, K. E., Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. 1987, 79 (3), 918-25.
[202]	Gerber, B. L.; Rochitte, C. E.; Melin, J. A.; McVeigh, E. R.; Bluemke, D. A.; Wu, K. C.; Becker, L. C.; Lima, J. A., Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000, 101 (23), 2734-41.
[203]	Siegbahn, A., Cellular consequences upon factor VIIa binding to tissue factor. Haemostasis 2000, 30 Suppl 2, 41-7.
[204]	Hjortoe, G. M.; Petersen, L. C.; Albrektsen, T.; Sorensen, B. B.; Norby, P. L.; Mandal, S. K.; Pendurthi, U. R.; Rao, L. V., Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004, 103 (8), 3029-37.
[205]	Butenas, S.; Brummel, K. E.; Branda, R. F.; Paradis, S. G.; Mann, K. G., Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002, 99 (3), 923-30.
[206]	Butenas, S.; Brummel, K. E.; Bouchard, B. A.; Mann, K. G., How factor VIIa works in hemophilia. J Thromb Haemost 2003, 1 (6), 1158-60.
[207]	Butenas, S.; van 't Veer, C.; Cawthern, K.; Brummel, K. E.; Mann, K. G., Models of blood coagulation. Blood Coagul. Fibrinolysis 2000, 11 Suppl 1, S9-13.
[208]	Himber, J.; Wohlgensinger, C.; Roux, S.; Damico, L. A.; Fallon, J. T.; Kirchhofer, D.; Nemerson, Y.; Riederer, M. A., Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 2003, 1 (5), 889-95.
[209]	Cirillo, P.; Cali, G.; Golino, P.; Calabro, P.; Forte, L.; De Rosa, S.; Pacileo, M.; Ragni, M.; Scopacasa, F.; Nitsch, L.; Chiariello, M., Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 2004, 109 (23), 2911-6.
[210]	Fleck, R. A.; Rao, L. V.; Rapaport, S. I.; Varki, N., Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb. Res. 1990, 59 (2), 421-37.
[211]	McVey, J. H., Tissue factor pathway. Baillieres Best Pract Res Clin Haematol 1999, 12 (3), 361-72.
[212]	Weiss, H. J.; Turitto, V. T.; Baumgartner, H. R.; Nemerson, Y.; Hoffmann, T., Evidence for the presence of tissue factor activity on subendothelium. Blood 1989, 73 (4), 968-75.
[213]	Welty-Wolf, K. E.; Carraway, M. S.; Miller, D. L.; Ortel, T. L.; Ezban, M.; Ghio, A. J.; Idell, S.; Piantadosi, C. A., Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am. J. Respir. Crit. Care Med. 2001, 164 (10 Pt 1), 1988-96.
[214]	Mullins, E. S.; Kombrinck, K. W.; Talmage, K. E.; Shaw, M. A.; Witte, D. P.; Ullman, J. M.; Degen, S. J.; Sun, W.; Flick, M. J.; Degen, J. L., Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood 2009, 113 (3), 696-704.
[215]	Audu, P.; Nielsen, V. G.; Armstead, V.; Powell, G.; Kim, J.; Kim, L.; Mehta, M., The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography. Anesth. Analg. 2006, 103 (4), 841-5.
[216]	Dalen, P.; Blomgren, K.; Bauer, J., [Warfarin can have a negative effect on bone formation]. Lakartidningen 1999, 96 (25), 3074.
[217]	Vinckier, F.; Vermylen, J., Wound healing following dental extractions in rabbits: effects of tranexamic acid, warfarin anti-coagulation, and socket packing. J. Dent. Res. 1984, 63 (5), 646-9.
[218]	Stvrtinova, V.; Ferencik, M.; Hulin, I.; Jahnova, E., [Vascular endothelium as a factor in information transfer between the cardiovascular and immune systems]. Bratisl. Lek. Listy 1998, 99 (1), 5-19.
[219]	Siegbahn, A.; Johnell, M.; Rorsman, C.; Ezban, M.; Heldin, C. H.; Ronnstrand, L., Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 2000, 96 (10), 3452-8.
[220]	Bajaj, M. S.; Birktoft, J. J.; Steer, S. A.; Bajaj, S. P., Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. 2001, 86 (4), 959-72.
[221]	Sajadi, S.; Ezekowitz, M. D.; Dhond, A.; Netrebko, P., Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspect 2003, 16 (6), 363-9.
[222]	Burnstock, G.; Ralevic, V., New insights into the local regulation of blood flow by perivascular nerves and endothelium. Br. J. Plast. Surg. 1994, 47 (8), 527-43.
[223]	Kvasnicka, T., [NO (nitric oxide) and its significance in regulation of vascular homeostasis]. Vnitr. Lek. 2003, 49 (4), 291-6.
[224]	Lau, C. S.; McLaren, M.; Belch, J. J., Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. Br. J. Rheumatol. 1991, 30 (6), 433-6.
[225]	Muller, A. M.; Skrzynski, C.; Skipka, G.; Muller, K. M., Expression of von Willebrand factor by human pulmonary endothelial cells in vivo. Respiration 2002, 69 (6), 526-33.
[226]	van Zwieten, P. A.; Doods, H. N., Muscarinic receptors and drugs in cardiovascular medicine. Cardiovasc. Drugs Ther. 1995, 9 (1), 159-67.
[227]	Esmon, C. T., Crosstalk between inflammation and thrombosis. Maturitas 2004, 47 (4), 305-14.
[228]	Zlokovic, B. V., Antithrombotic, procoagulant, and fibrinolytic mechanisms in cerebral circulation: implications for brain injury and protection. Neurosurg Focus 1997, 2 (6), e5.
[229]	Groebe, K., Precapillary servo control of blood pressure and postcapillary adjustment of flow to tissue metabolic status. A new paradigm for local perfusion regulation. Circulation 1996, 94 (8), 1876-85.
[230]	Park, G., Rescue is stressful. Anesth. Analg. 2002, 95 (2), 263-5.
[231]	Schneider, R. A., The relation of stress to clotting time, relative viscosity and certain other biophysical alterations of the blood in the nor-motensive and hypertensive subject. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 1949, 29, 818-31.
[232]	Penny, W. F.; Weinstein, M.; Salzman, E. W.; Ware, J. A., Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation 1991, 83 (5), 1630-6.
[233]	Cahalan, M. K.; Lurz, F. W.; Eger, E. I., 2nd; Schwartz, L. A.; Beaupre, P. N.; Smith, J. S., Narcotics decrease heart rate during inhalational anesthesia. Anesth. Analg. 1987, 66 (2), 166-70.
[234]	von Kries, R.; Jurgens, H.; von Voss, H.; Gobel, U., The clinical relevance of factor VIII: C and factor VII R: Ag determination in newborns. Eur. J. Pediatr. 1981, 137 (2), 189-94.
[235]	Kocsis, E.; Pacher, P.; Posa, I.; Nieszner, E.; Pogatsa, G.; Koltai, M. Z., Hyperglycaemia alters the endothelium-dependent relaxation of canine coronary arteries. Acta Physiol. Scand. 2000, 169 (3), 183-7.
[236]	Nees, S., The adenosine hypothesis of metabolic regulation of coronary flow in the light of newly recognized properties of the coronary endothelium. Z. Kardiol. 1989, 78 Suppl 6, 42-9.
[237]	Nees, S., Coronary flow increases induced by adenosine and adenine nucleotides are mediated by the coronary endothelium: a new principle of the regulation of coronary flow. Eur. Heart J. 1989, 10 Suppl F, 28-35.
[238]	Sielenkamper, A. W.; Eicker, K.; Van Aken, H., Thoracic epidural anesthesia increases mucosal perfusion in ileum of rats. Anesthesiology 2000, 93 (3), 844-51.
[239]	Akca, O.; Melischek, M.; Scheck, T.; Hellwagner, K.; Arkilic, C. F.; Kurz, A.; Kapral, S.; Heinz, T.; Lackner, F. X.; Sessler, D. I., Postoperative pain and subcutaneous oxygen tension. Lancet 1999, 354 (9172), 41-2.
[240]	Beyak, M. J.; Xue, S.; Collman, P. I.; Valdez, D. T.; Diamant, N. E., Central nervous system nitric oxide induces oropharyngeal swallowing and esophageal peristalsis in the cat. Gastroenterology 2000, 119 (2), 377-85.
[241]	Beyak, M. J.; Collman, P. I.; Xue, S.; Valdez, D. T.; Diamant, N. E., Release of nitric oxide in the central nervous system mediates tonic and phasic contraction of the cat lower oesophageal sphincter. Neurogastroenterol. Motil. 2003, 15 (4), 401-7.
[242]	Chohan, I. S.; Singh, I.; Vermylen, J.; Verstraete, M., Effect of furosemide on plasma fibrinolytic activity and urokinase excretion. Exp. Hematol. 1977, 5 (2), 153-7.
[243]	Kang, J. G.; Kim, J. K.; Jeong, H. S.; Jung, S. C.; Ko, M. H.; Park, S. H.; Cho, J. K.; Lee, G. J.; Choi, J. W.; Lee, B. D., A prospective, randomized comparison of the effects of inhaled sevoflurane anesthesia and propofol/remifentanil intravenous anesthesia on salivary excretion during laryngeal microsurgery. Anesth. Analg. 2008, 106 (6), 1723-7.
[244]	Klingel, R.; Fassbender, C.; Fischer, I.; Hattenbach, L.; Gumbel, H.; Pulido, J.; Koch, F., Rheopheresis for age-related macular degeneration: a novel indication for therapeutic apheresis in ophthalmology. Ther. Apher. 2002, 6 (4), 271-81.
[245]	Toda, N.; Ayajiki, K.; Okamura, T., Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol. Rev. 2007, 59 (1), 54-87.
[246]	Toda, N.; Ayajiki, K.; Okamura, T., Nitric oxide and penile erectile function. Pharmacol. Ther. 2005, 106 (2), 233-66.
[247]	Fagenholz, P. J.; Gutman, J. A.; Murray, A. F.; Harris, N. S., Treatment of high altitude pulmonary edema at 4240 m in Nepal. High Alt Med Biol 2007, 8 (2), 139-46.
[248]	O'Brodovich, H. M.; Andrew, M.; Gray, G. W.; Coates, G., Hypoxia alters blood coagulation during acute decompression in humans. J. Appl. Physiol. 1984, 56 (3), 666-70.
[249]	Bartsch, P.; Haeberli, A.; Franciolli, M.; Kruithof, E. K.; Straub, P. W., Coagulation and fibrinolysis in acute mountain sickness and beginning pulmonary edema. J. Appl. Physiol. 1989, 66 (5), 2136-44.
[250]	Kario, K.; McEwen, B. S.; Pickering, T. G., Disasters and the heart: a review of the effects of earthquake-induced stress on cardiovascular disease. Hypertens. Res. 2003, 26 (5), 355-67.
[251]	Barinov, V. G.; Zabelin, I. V.; Solo'vev, V. V., [Analysis of whole blood viscosity in patients with acute myocardial infarction using a rotation viscosimeter]. Lab. Delo 1989, (10), 25-7.
[252]	Bartsch, P.; Waber, U.; Haeberli, A.; Maggiorini, M.; Kriemler, S.; Oelz, O.; Straub, W. P., Enhanced fibrin formation in high-altitude pulmonary edema. J. Appl. Physiol. 1987, 63 (2), 752-7.
[253]	Chohan, I. S.; Singh, I.; Balakrihsnan, K., Fibri-nolytic activity at high altitude and sodium acetate buffer. Thromb. Diath. Haemorrh. 1974, 32 (1), 65-70.
[254]	Ito, H.; Taniyama, Y.; Iwakura, K.; Nishikawa, N.; Masuyama, T.; Kuzuya, T.; Hori, M.; Higashino, Y.; Fujii, K.; Minamino, T., Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol. 1999, 33 (3), 654-60.
[255]	Ito, H.; Okamura, A.; Iwakura, K.; Masuyama, T.; Hori, M.; Takiuchi, S.; Negoro, S.; Nakatsuchi, Y.; Taniyama, Y.; Higashino, Y.; Fujii, K.; Minamino, T., Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996, 93 (11), 1993-9.
[256]	Chiariello, M.; Brevetti, G.; Genovese, A.; Cataffo, A.; Ambrosio, G.; Condorelli, M. In Dilazep-induced reduction of ischemic necrosis in rats with coronary artery occlusion, Int. J. Cardiol., 1983; pp 339-48.
[257]	Das, B. B.; Wolfe, R. R.; Chan, K. C.; Larsen, G. L.; Reeves, J. T.; Ivy, D., High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch. Pediatr. Adolesc. Med. 2004, 158 (12), 1170-6.
[258]	Gasser, R.; Schafhalter-Zoppoth, I.; Schwarz, T.; Eber, B.; Koppel, H.; Lechleitner, P.; Puschendorf, B.; Dienstl, F.; Klein, W., Cyclic phenomena in early myocardial infarction. Acta Med. Austriaca 1995, 22 (4), 69-72.
[259]	Genovese, A.; Chiariello, M.; Latte, S.; de Alfieri, W.; Cacciapuoti, A. A.; Condorelli, M., Effects of antiplatelet and calcium antagonist drugs on infarct size in rats. Acta Cardiol. 1980, 35 (6), 419-27.
[260]	Gibson, C. M.; Murphy, S. A.; Rizzo, M. J.; Ryan, K. A.; Marble, S. J.; McCabe, C. H.; Cannon, C. P.; Van de Werf, F.; Braunwald, E., Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999, 99 (15), 1945-50.
[261]	Kloner, R. A.; Ganote, C. E.; Jennings, R. B., The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974, 54 (6), 1496-508.
[262]	Mann, K. G.; Butenas, S.; Brummel, K., The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol. 2003, 23 (1), 17-25.
[263]	Roe, M. T.; Ohman, E. M.; Maas, A. C.; Christenson, R. H.; Mahaffey, K. W.; Granger, C. B.; Harrington, R. A.; Califf, R. M.; Krucoff, M. W., Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J. Am. Coll. Cardiol. 2001, 37 (1), 9-18.
[264]	Rezkalla, S. H.; Kloner, R. A., No-reflow phenomenon. Circulation 2002, 105 (5), 656-62.
[265]	Segler, C. P., Prophylaxis of climbers for prevention of embolic accidents. Med. Hypotheses 2001, 57 (4), 472-5.
[266]	Wittstein, I. S.; Thiemann, D. R.; Lima, J. A.; Baughman, K. L.; Schulman, S. P.; Gerstenblith, G.; Wu, K. C.; Rade, J. J.; Bivalacqua, T. J.; Champion, H. C., Neurohumoral features of myocardial stunning due to sudden emotional stress. N. Engl. J. Med. 2005, 352 (6), 539-48.
[267]	Lip, G. Y.; Blann, A. D.; Jones, A. F.; Lip, P. L.; Beevers, D. G., Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am. J. Cardiol. 1997, 80 (12), 1566-71.
[268]	Bogar, L., Hemorheology and hypertension: not "chicken or egg" but two chickens from similar eggs. Clin. Hemorheol. Microcirc. 2002, 26 (2), 81-3.
[269]	Hlubocka, Z.; Umnerova, V.; Heller, S.; Peleska, J.; Jindra, A.; Jachymova, M.; Kvasnicka, J.; Aschermann, M.; Horky, K., [Is mild essential hypertension without obvious organ complications and risk factors associated with increased levels of circulating markers of endothelial dysfunction? Effect of ACE inhibitor therapy]. Vnitr. Lek. 2002, 48 (8), 718-23.
[270]	Choi, C. Q., Pressure Sensitive. Sci. Am. 2005, 293 (July), 98.
[271]	Cicco, G.; Vicenti, P.; Stingi, G. D.; Tarallo; Pirrelli, A., Hemorheology in complicated hypertension. Clin. Hemorheol. Microcirc. 1999, 21 (3-4), 315-9.
[272]	Danson, E. J.; Paterson, D. J., Reactive oxygen species and autonomic regulation of cardiac excitability. J. Cardiovasc. Electrophysiol. 2006, 17 Suppl 1, S104-S112.
[273]	Esler, M.; Rumantir, M.; Kaye, D.; Jennings, G.; Hastings, J.; Socratous, F.; Lambert, G., Sympathetic nerve biology in essential hypertension. Clin. Exp. Pharmacol. Physiol. 2001, 28 (12), 986-9.
[274]	Farkas, K.; Nemcsik, J.; Kolossvary, E.; Jarai, Z.; Nadory, E.; Farsang, C.; Kiss, I., Impairment of skin microvascular reactivity in hypertension and uraemia. Nephrol. Dial. Transplant. 2005, 20 (9), 1821-7.
[275]	Friedman, R.; Mears, J. G.; Barst, R. J., Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997, 96 (9), 2782-4.
[276]	Naeije, R.; Vachiery, J. L., Medical therapy of pulmonary hypertension. Conventional therapies. Clin. Chest Med. 2001, 22 (3), 517-27.
[277]	Savoia, C.; Schiffrin, E. L., Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens. 2006, 15 (2), 152-8.
[278]	Veyradier, A.; Nishikubo, T.; Humbert, M.; Wolf, M.; Sitbon, O.; Simonneau, G.; Girma, J. P.; Meyer, D., Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 2000, 102 (20), 2460-2.
[279]	Vicaut, E., Microcirculation and arterial hypertension. Drugs 1999, 59 Spec No, 1-10.
[280]	Grant, P. J., Hormonal regulation of the acute haemostatic response to stress. Blood Coagul. Fibrinolysis 1990, 1 (3), 299-306.
[281]	Hovinga, J. A.; Zeerleder, S.; Kessler, P.; de Wit, T. R.; van Mourik, J. A.; Hack, C. E.; Ten Cate, H.; Reitsma, P. H.; Wuillemin, W. A.; Lammle, B., ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007.
[282]	Sadler, J. E., von Willebrand factor. J. Biol. Chem. 1991, 266 (34), 22777-80.
[283]	Sadler, J. E.; Budde, U.; Eikenboom, J. C.; Favaloro, E. J.; Hill, F. G.; Holmberg, L.; Ingerslev, J.; Lee, C. A.; Lillicrap, D.; Mannucci, P. M.; Mazurier, C.; Meyer, D.; Nichols, W. L.; Nishino, M.; Peake, I. R.; Rodeghiero, F.; Schneppenheim, R.; Ruggeri, Z. M.; Srivastava, A.; Montgomery, R. R.; Federici, A. B., Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006.
[284]	van Mourik, J. A.; Boertjes, R.; Huisveld, I. A.; Fijnvandraat, K.; Pajkrt, D.; van Genderen, P. J.; Fijnheer, R., von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999, 94 (1), 179-85.
[285]	Mannucci, P. M.; Ruggeri, Z. M.; Gagnatelli, G., Nervous regulation of factor-VIII levels in man. Br. J. Haematol. 1971, 20 (2), 195-207.
[286]	Federici, A. B., The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 2003, 88 (6), EREP02.
[287]	Anderson, L. C.; Martin, D. J.; Phillips, D. L.; Killpack, K. J.; Bone, S. E.; Rahimian, R., The influence of gender on parasympathetic vasodilatation in the submandibular gland of the rat. Exp. Physiol. 2006, 91 (2), 435-44.
[288]	Hudetz, A. G., The cerebral microcirculation in ischemia and hypoxemia. The Arisztid G. B. Kovach Memorial Lecture. Adv. Exp. Med. Biol. 2003, 530, 347-57.
[289]	Hudetz, A. G., Regulation of oxygen supply in the cerebral circulation. Adv. Exp. Med. Biol. 1997, 428, 513-20.
[290]	Dijkstra, G.; van Goor, H.; Jansen, P. L.; Moshage, H., Targeting nitric oxide in the gastrointestinal tract. Curr Opin Investig Drugs 2004, 5 (5), 529-36.
[291]	Amano, M.; Takahashi, M.; Kosaka, T.; Kinoshita, M., Differential inhibition of platelet aggregation and calcium mobilization by nitroglycerin and stabilized nitric oxide. J. Cardiovasc. Pharmacol. 1994, 24 (6), 860-6.
[292]	Baskurt, O. K.; Yalcin, O.; Ozdem, S.; Armstrong, J. K.; Meiselman, H. J., Modulation of endothelial nitric oxide synthase expression by red blood cell aggregation. Am J Physiol Heart Circ Physiol 2004, 286 (1), H222-9.
[293]	Brugger, W.; Imhof, P.; Muller, P.; Moser, P.; Reubi, F., Effect of nitroglycerin on blood rheology in healthy subjects. Eur. J. Clin. Pharmacol. 1985, 29 (3), 331-6.
[294]	Epstein, S. E.; Borer, J. S.; Kent, K. M.; Redwood, D. R.; Goldstein, R. E.; Levitt, B., Protection of ischemic myocardium by nitroglycerin: experimental and clinical results. Circulation 1976, 53 (3 Suppl), I191-8.
[295]	Fricchione, G. L.; Bilfinger, T. V.; Hartman, A.; Liu, Y.; Stefano, G. B., Neuroimmunologic implications in coronary artery disease. Adv. Neuroimmunol. 1996, 6 (2), 131-42.
[296]	Webb, D. J.; Muirhead, G. J.; Wulff, M.; Sutton, J. A.; Levi, R.; Dinsmore, W. W., Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J. Am. Coll. Cardiol. 2000, 36 (1), 25-31.
[297]	Griffin, J. H.; Fernandez, J. A.; Gale, A. J.; Mosnier, L. O., Activated protein C. J Thromb Haemost 2007, 5 Suppl 1, 73-80.
[298]	Hoppensteadt, D. A.; Fareed, J.; Raake, P.; Raake, W., Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates. Thromb. Res. 2001, 103 (2), 157-63.
[299]	Mosnier, L. O.; Yang, X. V.; Griffin, J. H., Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J. Biol. Chem. 2007, 282 (45), 33022-33.
[300]	Robriquet, L.; Collet, F.; Tournoys, A.; Prangere, T.; Neviere, R.; Fourrier, F.; Guery, B. P., Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 2006, 7, 41.
[301]	van der Poll, T.; Levi, M.; Nick, J. A.; Abraham, E., Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am. J. Respir. Crit. Care Med. 2005, 171 (10), 1125-8.
[302]	Ades, P. A.; Waldmann, M. L.; Meyer, W. L.; Brown, K. A.; Poehlman, E. T.; Pendlebury, W. W.; Leslie, K. O.; Gray, P. R.; Lew, R. R.; LeWinter, M. M., Skeletal muscle and cardiovascular adaptations to exercise conditioning in older coronary patients. Circulation 1996, 94 (3), 323-30.
[303]	Franzoni, F.; Plantinga, Y.; Femia, F. R.; Bartolomucci, F.; Gaudio, C.; Regoli, F.; Carpi, A.; Santoro, G.; Galetta, F., Plasma antioxidant activity and cutaneous microvascular endothelial function in athletes and sedentary controls. Biomed. Pharmacother. 2004, 58 (8), 432-6.
[304]	Rao, K.; Fisher, M. L.; Robinson, S.; Shorofsky, S.; Gottlieb, S. S., Effect of chronic changes in heart rate on congestive heart failure. J. Card. Fail. 2007, 13 (4), 269-74.
[305]	Eichner, E. R., Exercise and heart disease. Epidemiology of the "exercise hypothesis". Am. J. Med. 1983, 75 (6), 1008-23.
[306]	Schmermund, A., [Cardiorespiratory fitness. Importance of exercise for healthiness]. Herz 2004, 29 (4), 365-72.
[307]	Carr, M. E., Diabetes mellitus: a hypercoagulable state. J. Diabetes Complications 2001, 15 (1), 44-54.
[308]	Zanesco, A.; Antunes, E., Effects of exercise training on the cardiovascular system: Pharmacological approaches. Pharmacol. Ther. 2007, 114 (3), 307-17.
[309]	Sandercock, G. R.; Bromley, P. D.; Brodie, D. A., Effects of exercise on heart rate variability: inferences from meta-analysis. Med. Sci. Sports Exerc. 2005, 37 (3), 433-9.
[310]	van den Burg, P. J.; Hospers, J. E.; Mosterd, W. L.; Bouma, B. N.; Huisveld, I. A., Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products. J. Appl. Physiol. 2000, 88 (5), 1558-64.
[311]	Prior, B. M.; Lloyd, P. G.; Yang, H. T.; Terjung, R. L., Exercise-induced vascular remodeling. Exerc. Sport Sci. Rev. 2003, 31 (1), 26-33.
[312]	Lloyd, P. G.; Prior, B. M.; Li, H.; Yang, H. T.; Terjung, R. L., VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats. Am J Physiol Heart Circ Physiol 2005, 288 (2), H759-68.
[313]	Wijnen, J. A.; Kool, M. J.; van Baak, M. A.; Kuipers, H.; de Haan, C. H.; Verstappen, F. T.; Struijker Boudier, H. A.; Van Bortel, L. M., Effect of exercise training on ambulatory blood pressure. Int. J. Sports Med. 1994, 15 (1), 10-5.
[314]	Baron, A. D., Hemodynamic actions of insulin. Am. J. Physiol. 1994, 267 (2 Pt 1), E187-202.
[315]	Lee, Y. H.; Wei, F. C.; Lee, J.; Su, M. S., Microcirculatory changes following reperfusion insult in diabetic rat skeletal muscles. Microsurgery 2000, 20 (2), 77-84.
[316]	Yi, Y.; Baoyu, W.; Shenyuan, Y.; Liangxiang, Z.; Hanqing, F.; Yuantao, L., Changes of nailfold microcirculation in patients of type II diabetes mellitus with diabetic retinopathy. Chin. Med. Sci. J. 1999, 14 (4), 233-6.
[317]	Long, Z. F.; Qu, G. Y.; Xu, M., [Relationship between the level of plasma D-dimer and diabetic microangiopathy]. Hunan Yi Ke Da Xue Xue Bao 2001, 26 (5), 434-6.
[318]	Phillip, B.; Pastor, D.; Bellows, W.; Leung, J. M., The prevalence of preoperative diastolic filling abnormalities in geriatric surgical patients. Anesth. Analg. 2003, 97 (5), 1214-21.
[319]	Chen, J.; Goligorsky, M. S., Premature senes-cence of endothelial cells: Methusaleh's dilemma. Am J Physiol Heart Circ Physiol 2006, 290 (5), H1729-39.
[320]	Rakusan, K.; Nagai, J., Morphometry of arterioles and capillaries in hearts of senescent mice. Cardiovasc. Res. 1994, 28 (7), 969-72.
[321]	Boudier, H. A., Arteriolar and capillary remodelling in hypertension. Drugs 1999, 58 Spec No 1, 37-40.
[322]	Kawut, S. M.; Horn, E. M.; Berekashvili, K. K.; Garofano, R. P.; Goldsmith, R. L.; Widlitz, A. C.; Rosenzweig, E. B.; Kerstein, D.; Barst, R. J., New predictors of outcome in idiopathic pulmonary arterial hypertension. Am. J. Cardiol. 2005, 95 (2), 199-203.
[323]	Kawut, S. M.; Horn, E. M.; Berekashvili, K. K.; Widlitz, A. C.; Rosenzweig, E. B.; Barst, R. J., von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005, 128 (4), 2355-62.
[324]	Lip, G. Y.; Edmunds, E.; Nuttall, S. L.; Landray, M. J.; Blann, A. D.; Beevers, D. G., Oxidative stress in malignant and non-malignant phase hypertension. J. Hum. Hypertens. 2002, 16 (5), 333-6.
[325]	Lip, G. Y.; Edmunds, E.; Hee, F. L.; Blann, A. D.; Beevers, D. G., A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am. J. Hypertens. 2001, 14 (8 Pt 1), 823-8.
[326]	Lip, G. Y.; Blann, A. D.; Edmunds, E.; Beevers, D. G., Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul. Fibrinolysis 2002, 13 (1), 35-41.
[327]	Ventura, H.; Messerli, F. H.; Oigman, W.; Suarez, D. H.; Dreslinski, G. R.; Dunn, F. G.; Reisin, E.; Frohlich, E. D., Impaired systemic arterial compliance in borderline hypertension. Am. Heart J. 1984, 108 (1), 132-6.
[328]	Huang, F. Y.; Chen, T. L.; Fan, S. Z.; Sun, W. Z., Microvascular perfusion and resistance in extracorporeal cardiopulmonary bypass under hypothermia with high-dose narcotic anesthesia-animal model. Ma Zui Xue Za Zhi 1990, 28 (1), 1-8.
[329]	Ito, H.; Iwakura, K., Assessing the relation between coronary reflow and myocardial reflow. Am. J. Cardiol. 1998, 81 (12A), 8G-12G.
[330]	Trachte, A. L.; Lobato, E. B.; Urdaneta, F.; Hess, P. J.; Klodell, C. T.; Martin, T. D.; Staples, E. D.; Beaver, T. M., Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann. Thorac. Surg. 2005, 79 (1), 194-7; discussion 194-7.
[331]	Behr-Roussel, D.; Oudot, A.; Caisey, S.; Coz, O. L.; Gorny, D.; Bernabe, J.; Wayman, C.; Alexandre, L.; Giuliano, F. A., Daily Treatment with Sildenafil Reverses Endothelial Dysfunction and Oxidative Stress in an Animal Model of Insulin Resistance. Eur. Urol. 2007.
[332]	Ciardella, A. P., Partial resolution of diabetic macular oedema after systemic treatment with furosemide. Br. J. Ophthalmol. 2004, 88 (9), 1224-5.
[333]	Korom, S.; Hillinger, S.; Cardell, M.; Zhai, W.; Tan, Q.; Dutly, A.; Leskosek, B.; Weder, W., Sildenafil extends survival and graft function in a large animal lung transplantation model. Eur. J. Cardiothorac. Surg. 2006, 29 (3), 288-93.
[334]	Lewis, G. D.; Shah, R.; Shahzad, K.; Camuso, J. M.; Pappagianopoulos, P. P.; Hung, J.; Tawakol, A.; Gerszten, R. E.; Systrom, D. M.; Bloch, K. D.; Semigran, M. J., Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension. Circulation 2007.
[335]	Casonato, A.; Pontara, E.; Bertomoro, A.; Cattini, M. G.; Soldera, C.; Girolami, A., Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. Haematologica 2003, 88 (6), 688-93.
[336]	Witte, S., The role of blood coagulation in capillary permeability Vitalmicroscopic contributions. Biorheology 1984, 21 (1-2), 121-33.
[337]	Wojtarowicz, A.; Podlasz, P.; Czaja, K., Adrenergic and cholinergic innervation of pulmonary tissue in the pig. Folia Morphol. (Warsz). 2003, 62 (3), 215-8.
[338]	Martin, M. J.; Jimenez, M. D.; Motilva, V., New issues about nitric oxide and its effects on the gastrointestinal tract. Curr. Pharm. Des. 2001, 7 (10), 881-908.
[339]	Morita-Tsuzuki, Y.; Hardebo, J. E.; Bouskela, E., Inhibition of nitric oxide synthase attenuates the cerebral blood flow response to stimulation of postganglionic parasympathetic nerves in the rat. J. Cereb. Blood Flow Metab. 1993, 13 (6), 993-7.
[340]	Kvist-Reimer, M.; Sundler, F.; Ahren, B., Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice. Cell Tissue Res. 2002, 307 (2), 203-9.
[341]	Watkins, C. C.; Sawa, A.; Jaffrey, S.; Blackshaw, S.; Barrow, R. K.; Snyder, S. H.; Ferris, C. D., Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J. Clin. Invest. 2000, 106 (6), 803.
[342]	Vincent, M. A.; Montagnani, M.; Quon, M. J., Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003, 3 (4), 279-88.
[343]	Wamhoff, D.; Weiss, D.; Senf, L., [Studies on the influence of glucose infusion on parameters of hemostasis]. Z. Gesamte Inn. Med. 1976, 31 (17), 711-5.
[344]	Ahmed, M. H., Chloroquine-induced nitric oxide improves insulin sensitivity in rheumatoid arthritis. In Med. Hypotheses, 2006; Vol. 66, pp 208-9.
[345]	Ali, S. T.; Rakkah, N. I., Neurophysiological role of sildenafil citrate (Viagra) on seminal parameters in diabetic males with and without neuropathy. Pak J Pharm Sci 2007, 20 (1), 36-42.
[346]	Ayala, J. E.; Bracy, D. P.; Julien, B. M.; Rottman, J. N.; Fueger, P. T.; Wasserman, D. H., Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007, 56 (4), 1025-33.
[347]	Belcaro, G.; Marelli, C.; Pomante, P.; Laurora, G.; Cesarone, M. R.; Ricci, A.; Girardello, R.; Barsotti, A., Fibrinolytic enhancement in diabetic microangiopathy with defibrotide. Angiology 1992, 43 (10), 793-800.
[348]	Colantuoni, A.; Lapi, D.; Paterni, M.; Marchiafava, P. L., Protective effects of insulin during ischemia-reperfusion injury in hamster cheek pouch microcirculation. J. Vasc. Res. 2005, 42 (1), 55-66.
[349]	Figueras, J.; Singh, B. N.; Ganz, W.; Swan, H. J., Haemodynamic and electrocardiographic accompaniments of resting postprandial angina. Br. Heart J. 1979, 42 (4), 402-9.
[350]	Parker, J. D.; Bart, B. A.; Webb, D. J.; Koren, M. J.; Siegel, R. L.; Wang, H.; Malhotra, B.; Jen, F.; Glue, P., Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Crit. Care Med. 2007, 35 (8), 1863-1868.
[351]	Rich, S.; Kaufmann, E.; Levy, P. S., The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 1992, 327 (2), 76-81.
[352]	Singh, G.; Chaudry, K. I.; Chaudry, I. H., Diltiazem reduces whole blood viscosity following trauma-hemorrhagic shock and resuscitation. Circ. Shock 1993, 39 (3), 231-6.
[353]	Brandi, L. S.; Frediani, M.; Oleggini, M.; Mosca, F.; Cerri, M.; Boni, C.; Pecori, N.; Buzzigoli, G.; Ferrannini, E., Insulin resistance after surgery: normalization by insulin treatment. Clin Sci (Lond) 1990, 79 (5), 443-50.
[354]	Adamiec, R.; Bednarska-Chabowska, D.; Adamiec, J.; Wdowczyk, M., [Contribution of selected factors of inflammatory creative process in the vascular endothelial damage in the diabetes patients]. Pol. Arch. Med. Wewn. 2003, 110 (1), 683-9.
[355]	Caruso, S.; Rugolo, S.; Mirabella, D.; Intelisano, G.; Di Mari, L.; Cianci, A., Changes in clitoral blood flow in premenopausal women affected by type 1 diabetes after single 100-mg administration of sildenafil. Urology 2006, 68 (1), 161-5.
[356]	Caruso, S.; Rugolo, S.; Agnello, C.; Intelisano, G.; Di Mari, L.; Cianci, A., Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil. Steril. 2006, 85 (5), 1496-501.
[357]	Hassoun, P. M.; Thompson, B. T.; Steigman, D.; Hales, C. A., Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig. Am. Rev. Respir. Dis. 1989, 139 (3), 763-8.
[358]	He, G. Z., [Study on the fibrin fibrinogen degradation products levels and it's significance in the phlegm of the patients with chronic cor pulmonale through monoclonal antibodies]. Zhonghua Jie He He Hu Xi Za Zhi 1990, 13 (3), 154-6, 191.
[359]	Khan, T. M.; Marwat, M. A.; Rehman, H., Comparison of plasma viscosity and fibrinogen concentration in hypertensive and normotensive diabetics. J Ayub Med Coll Abbottabad 2005, 17 (4), 45-7.
[360]	McDonagh, P. F.; Hokama, J. Y., Microvascular perfusion and transport in the diabetic heart. Microcirculation 2000, 7 (3), 163-81.
[361]	Messerli, F. H.; Williams, B.; Ritz, E., Essential hypertension. Lancet 2007, 370 (9587), 591-603.
[362]	Schafer, A.; Fraccarollo, D.; Pfortsch, S.; Flierl, U.; Vogt, C.; Pfrang, J.; Kobsar, A.; Renne, T.; Eigenthaler, M.; Ertl, G.; Bauersachs, J., Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br. J. Pharmacol. 2008, 153 (5), 886-93.
[363]	Wallis, M. G.; Smith, M. E.; Kolka, C. M.; Zhang, L.; Richards, S. M.; Rattigan, S.; Clark, M. G., Acute glucosamine-induced insulin resistance in muscle in vivo is associated with impaired capillary recruitment. Diabetologia 2005, 48 (10), 2131-9.
[364]	dKim, J. A.; Tran, N. D.; Wang, S. J.; Fisher, M. J., Astrocyte regulation of human brain capillary endothelial fibrinolysis. Thromb. Res. 2003, 112 (3), 159-65.
[365]	Kranenburg, O.; Bouma, B.; Kroon-Batenburg, L. M.; Reijerkerk, A.; Wu, Y. P.; Voest, E. E.; Gebbink, M. F., Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 2002, 12 (21), 1833-9.
[366]	Leibovitz, E.; Harpaz, D.; Elly, I.; Klepfish, A.; Gavish, D., Persistent anemia in otherwise asymptomatic severe aortic stenosis: a possible indication for valve replacement? Isr Med Assoc J 2004, 6 (7), 400-2.
[367]	O'Brien, J. R., Angiodysplasia, haemostasis and capillaries. A hypothesis. Thromb. Res. 1996, 84 (5), 385-7.
[368]	Basso, I. N.; Keeling, D., Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul. Fibrinolysis 2004, 15 (6), 503-4.
[369]	Fujita, H.; Tomiyama, J.; Chuganji, Y.; Momoi, M.; Tanaka, T., Diffuse angiodysplasia of the upper gastrointestinal tract in a patient with hypertrophic obstructive cardiomyopathy. Intern. Med. 2000, 39 (5), 385-8.
[370]	Koscielny, J. K.; Latza, R.; Mursdorf, S.; Mrowietz, C.; Kiesewetter, H.; Wenzel, E.; Jung, F., Capillary microscopic and rheological dimensions for the diagnosis of von Willebrand disease in comparison to other haemorrhagic diatheses. Thromb. Haemost. 2000, 84 (6), 981-8.
[371]	Rodeghiero, F., von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002, 8 (3), 292-300.
[372]	Rosborough, T. K.; Swaim, W. R., Acquired von Willebrand's disease, platelet-release defect and angiodysplasia. Am. J. Med. 1978, 65 (1), 96-100.
[373]	Veyradier, A.; Balian, A.; Wolf, M.; Giraud, V.; Montembault, S.; Obert, B.; Dagher, I.; Chaput, J. C.; Meyer, D.; Naveau, S., Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001, 120 (2), 346-53.
[374]	Warkentin, T. E.; Moore, J. C.; Anand, S. S.; Lonn, E. M.; Morgan, D. G., Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus. Med. Rev. 2003, 17 (4), 272-86.
[375]	Ferrell, W. J.; Jabs, C. M.; Robb, H. J.; Mammen, E. F., Comparative study of blood clotting factors in anaphylactic and primary and secondary endotoxin shock. Ann. Clin. Lab. Sci. 1983, 13 (4), 291-8.
[376]	Bergamaschini, L.; Santangelo, T.; Faricciotti, A.; Ciavarella, N.; Mannucci, P. M.; Agostoni, A., Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes. J. Immunol. 1996, 156 (3), 1256-61.
[377]	Bergamaschini, L.; Mannucci, P. M.; Federici, A. B.; Coppola, R.; Guzzoni, S.; Agostoni, A., Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J. Lab. Clin. Med. 1995, 125 (3), 348-55.
[378]	Koch, B.; Galioto, F. M., Jr.; Kelleher, J.; Goldstein, D., Physical fitness in children with hemophilia. Arch. Phys. Med. Rehabil. 1984, 65 (6), 324-6.
[379]	Jadhav, M.; Warrier, I., Anaphylaxis in patients with hemophilia. Semin. Thromb. Hemost. 2000, 26 (2), 205-8.
[380]	Kadar, J. G.; Schuster, J.; Hunzelmann, N., IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. Haemophilia 2007, 13 (1), 104-5.
[381]	Lindenfeld, J.; Weil, J. V.; Travis, V. L.; Horwitz, L. D., Regulation of oxygen delivery during induced polycythemia in exercising dogs. Am J Physiol Heart Circ Physiol 2005, 289 (5), H1821-5.
[382]	Suttner, S.; Piper, S. N.; Kumle, B.; Lang, K.; Rohm, K. D.; Isgro, F.; Boldt, J., The influence of allogeneic red blood cell transfusion compared with 100% oxygen ventilation on systemic oxygen transport and skeletal muscle oxygen tension after cardiac surgery. Anesth. Analg. 2004, 99 (1), 2-11.
[383]	Lindenfeld, J.; Weil, J. V.; Travis, V. L.; Horwitz, L. D., Hemodynamic response to normovolemic polycythemia at rest and during exercise in dogs. Circ. Res. 1985, 56 (6), 793-800.
[384]	Tous, M.; Ferre, N.; Vilella, E.; Riu, F.; Camps, J.; Joven, J., Circulating blood cells modulate the atherosclerotic process in apolipoprotein E-deficient mice. Metabolism. 2004, 53 (1), 95-100.
[385]	Cinar, Y.; Demir, G.; Pac, M.; Cinar, A. B., Effect of hematocrit on blood pressure via hyperviscosity. Am. J. Hypertens. 1999, 12 (7), 739-43.
[386]	Hof, B.; van Doorne, C. W.; Westerweel, J.; Nieuwstadt, F. T.; Faisst, H.; Eckhardt, B.; Wedin, H.; Kerswell, R. R.; Waleffe, F., Experimental observation of nonlinear trav-eling waves in turbulent pipe flow. Science 2004, 305 (5690), 1594-8.
[387]	Baskurt, O. K.; Meiselman, H. J., RBC aggregation: more important than RBC adhesion to endothelial cells as a determinant of in vivo blood flow in health and disease. Microcirculation 2008, 15 (7), 585-90.
[388]	Baskurt, O. K.; Meiselman, H. J., Hemodynamic effects of red blood cell aggregation. Indian J. Exp. Biol. 2007, 45 (1), 25-31.
[389]	Baskurt, O. K.; Meiselman, H. J., Blood rheology and hemodynamics. Semin. Thromb. Hemost. 2003, 29 (5), 435-50.
[390]	Meiselman, H. J.; Neu, B.; Rampling, M. W.; Baskurt, O. K., RBC aggregation: laboratory data and models. Indian J. Exp. Biol. 2007, 45 (1), 9-17.
[391]	Rampling, M. W.; Meiselman, H. J.; Neu, B.; Baskurt, O. K., Influence of cell-specific factors on red blood cell aggregation. Biorheology 2004, 41 (2), 91-112.
[392]	Seo, T.; Fujita, H.; Ikeda, Y.; Hayashi, T.; Kawaguchi, K.; Kotake, C.; Ueda, S.; Kirime, S.; Toda, T.; Kobayashi, K., [A case of multiple myeloma with heart failure improved remarkably by chemotherapy alone]. Kokyu To. Junkan. 1991, 39 (6), 601-5.
[393]	Yalcin, O.; Uyuklu, M.; Armstrong, J. K.; Meiselman, H. J.; Baskurt, O. K., Graded alterations of RBC aggregation influence in vivo blood flow resistance. Am J Physiol Heart Circ Physiol 2004, 287 (6), H2644-50.
[394]	Holt, J. P.; Rhode, E. A.; Kines, H., Ventricular volumes and body weight in mammals. Am. J. Physiol. 1968, 215 (3), 704-15.
[395]	Parker, K. H., Instability in Arterial Blood Flow. University Park Press, Chamber of Commerce Building, Baltimore, Md. 21202: Baltimore, Md, 1977.
[396]	Laurent, P.; Albaladejo, P.; Blacher, J.; Rudnichi, A.; Smulyan, H.; Safar, M. E., Heart rate and pulse pressure amplification in hypertensive subjects. Am. J. Hypertens. 2003, 16 (5 Pt 1), 363-70.
[397]	Bogar, L.; Juricskay, I.; Kesmarky, G.; Kenyeres, P.; Toth, K., Erythrocyte transport efficacy of human blood: a rheological point of view. Eur. J. Clin. Invest. 2005, 35 (11), 687-90.
[398]	Couch, P.; Stumpf, J. L., Management of uremic bleeding. Clin. Pharm. 1990, 9 (9), 673-81.
[399]	Casonato, A.; Pontara, E.; Vertolli, U. P.; Steffan, A.; Durante, C.; De Marco, L.; Sartorello, F.; Girolami, A., Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. Clin Appl Thromb Hemost 2001, 7 (2), 81-6.
[400]	Fernandez, F.; Goudable, C.; Sie, P.; Ton-That, H.; Durand, D.; Suc, J. M.; Boneu, B., Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br. J. Haematol. 1985, 59 (1), 139-48.
[401]	Hardy, J. F.; de Moerloose, P.; Samama, C. M., Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can. J. Anaesth. 2006, 53 (6 Suppl), S40-58.
[402]	Kwaan, H. C.; Wang, J., Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin. Thromb. Hemost. 2003, 29 (5), 451-8.
[403]	Quaknine-Orlando, B.; Samama, C. M.; Riou, B.; Bonnin, P.; Guillosson, J. J.; Beaumont, J. L.; Coriat, P., Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology 1999, 90 (5), 1454-61.
[404]	Chris Woodyard, P. D. a. B. H. BP spill highlights aging oil field's increasing problems USA Today [Online], 2006. http://www.usatoday.com/money/industries/energy/2006-08-14-bp-cover-usat_x.htm?POE=click-refer.
[405]	Glagov, S.; Zarins, C.; Giddens, D. P.; Ku, D. N., Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch. Pathol. Lab. Med. 1988, 112 (10), 1018-31.
[406]	Glagov, S.; Bassiouny, H. S.; Giddens, D. P.; Zarins, C. K., Pathobiology of plaque modeling and complication. Surg. Clin. North Am. 1995, 75 (4), 545-56.
[407]	Giddens, D. P.; Zarins, C. K.; Glagov, S., The role of fluid mechanics in the localization and detection of atherosclerosis. J. Biomech. Eng. 1993, 115 (4B), 588-94.
[408]	Bassiouny, H. S.; Zarins, C. K.; Kadowaki, M. H.; Glagov, S., Hemodynamic stress and experimental aortoiliac atherosclerosis. J. Vasc. Surg. 1994, 19 (3), 426-34.
[409]	Davies, P. F., Flow-mediated endothelial mechanotransduction. Physiol. Rev. 1995, 75 (3), 519-60.
[410]	Chesebro, J. H.; Badimon, J. J.; Hassinger, N. L.; McBane, R. D.; Fuster, V. V., Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin. J. Thromb. Thrombolysis 1995, 1 (3), 231-235.
[411]	Gordon, J. B.; Ganz, P.; Nabel, E. G.; Fish, R. D.; Zebede, J.; Mudge, G. H.; Alexander, R. W.; Selwyn, A. P., Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J. Clin. Invest. 1989, 83 (6), 1946-52.
[412]	Kaunitz, H., [The significance of dietary fat in arteriosclerosis. An outmoded theory? (author's transl)]. MMW. Munch. Med. Wochenschr. 1977, 119 (16), 539-42.
[413]	Kensey, K. R., The mechanistic relationships between hemorheological characteristics and cardiovascular disease. Curr. Med. Res. Opin. 2003, 19 (7), 587-96.
[414]	Malek, A. M.; Alper, S. L.; Izumo, S., Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999, 282 (21), 2035-42.
[415]	Ross, R., Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340 (2), 115-126.
[416]	Silber, H. A.; Bluemke, D. A.; Ouyang, P.; Du, Y. P.; Post, W. S.; Lima, J. A., The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. J. Am. Coll. Cardiol. 2001, 38 (7), 1859-65.
[417]	Nerem, R. M.; Seed, W. A., An in vivo study of aortic flow disturbances. Cardiovasc. Res. 1972, 6 (1), 1-14.
[418]	Katritsis, D.; Kaiktsis, L.; Chaniotis, A.; Pantos, J.; Efstathopoulos, E. P.; Marmarelis, V., Wall shear stress: theoretical considerations and methods of measurement. Prog. Cardiovasc. Dis. 2007, 49 (5), 307-29.
[419]	Ku, D. N.; Giddens, D. P.; Zarins, C. K.; Glagov, S., Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985, 5 (3), 293-302.
[420]	Zhao, S. Z.; Xu, X. Y.; Hughes, A. D.; Thom, S. A.; Stanton, A. V.; Ariff, B.; Long, Q., Blood flow and vessel mechanics in a physiologically realistic model of a human carotid arterial bifurcation. J. Biomech. 2000, 33 (8), 975-84.
[421]	Zhao, S. Z.; Ariff, B.; Long, Q.; Hughes, A. D.; Thom, S. A.; Stanton, A. V.; Xu, X. Y., Inter-individual variations in wall shear stress and mechanical stress distributions at the carotid artery bifurcation of healthy humans. J. Biomech. 2002, 35 (10), 1367-77.
[422]	Biondi, B.; Palmieri, E. A.; Lombardi, G.; Fazio, S., Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med. 2002, 137 (11), 904-14.
[423]	Biondi, B.; Klein, I., Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004, 24 (1), 1-13.
[424]	Chambless, L. E.; Folsom, A. R.; Sharrett, A. R.; Sorlie, P.; Couper, D.; Szklo, M.; Nieto, F. J., Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J. Clin. Epidemiol. 2003, 56 (9), 880-90.
[425]	Donders, S. H.; Lustermans, F. A.; Van Wersch, J. W., Coagulation factors and lipid composition of the blood in treated and untreated hypertensive patients. Scand. J. Clin. Lab. Invest. 1993, 53 (2), 179-86.
[426]	Fazio, S.; Palmieri, E. A.; Lombardi, G.; Biondi, B., Effects of thyroid hormone on the cardiovascular system. Recent Prog. Horm. Res. 2004, 59, 31-50.
[427]	Mehta, J.; Singhal, S., Hyperviscosity syndrome in plasma cell dyscrasias. Semin. Thromb. Hemost. 2003, 29 (5), 467-71.
[428]	Powell, J.; Zadeh, J. A.; Carter, G.; Greenhalgh, R. M.; Fowler, P. B., Raised serum thyrotrophin in women with peripheral arterial disease. Br. J. Surg. 1987, 74 (12), 1139-41.
[429]	Roguski, J.; Durkalec, J.; Hasik, J.; Jaroszewski, F.; Krasnik, W.; Nowaczyk, J.; Rachlewicz, J.; Roguska, J.; Ruszkowski, M., Incidence of Clinical Criteria of Atherosclerosis in Hypo- and Hyperthyroidism, Polycythaemia Vera and Chronic Cor Pulmonale (Para- and Antiatherosclerotic Syndromes). Cor Vasa 1964, 103, 219-30.
[430]	Rosenson, R. S.; Shott, S.; Katz, R., Elevated blood viscosity in systemic lupus erythematosus. Semin. Arthritis Rheum. 2001, 31 (1), 52-7.
[431]	Wolak, T.; Todosoui, E.; Szendro, G.; Bolotin, A.; Jonathan, B. S.; Flusser, D.; Buskila, D.; Sukenik, S.; Abu-Shakra, M., Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J. Rheumatol. 2004, 31 (5), 909-14.
[432]	Alexandrov, A. V.; Molina, C. A.; Grotta, J. C.; Garami, Z.; Ford, S. R.; Alvarez-Sabin, J.; Montaner, J.; Saqqur, M.; Demchuk, A. M.; Moye, L. A.; Hill, M. D.; Wojner, A. W., Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 2004, 351 (21), 2170-8.
[433]	Britton, B. J.; Hawkey, C.; Wood, W. G.; Peele, M., Stress-a significant factor in venous thrombosis? Br J Surg 1974, 61 (10), 814-20.
[434]	Stuart, J.; George, A. J.; Davies, A. J.; Aukland, A.; Hurlow, R. A., Haematological stress syndrome in atherosclerosis. J. Clin. Pathol. 1981, 34 (5), 464-7.
[435]	Francis, R. B., Jr., Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 1989, 19 (2), 105-11.
[436]	Aluoch, J. R., Fibrinolytic activity in adult Kenyan patients with sickle cell disease. East Afr. Med. J. 1998, 75 (6), 351-2.
[437]	Devine, D. V.; Kinney, T. R.; Thomas, P. F.; Rosse, W. F.; Greenberg, C. S., Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease. Blood 1986, 68 (1), 317-9.
[438]	Famodu, A. A., Plasma fibrinolytic activity in sickle cell disease. Trop. Geogr. Med. 1988, 40 (4), 331-3.
[439]	Salvaggio, J. E.; Arnold, C. A.; Banov, C. H., Long-term anti-coagulation in sickle-cell disease. A clinical study. N. Engl. J. Med. 1963, 269, 182-6.
[440]	Solomon, L. R., Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008, 111 (3), 997-1003.
[441]	Chang, S. J.; Koh, S. B.; Cha, B. S.; Park, J. K., Job characteristics and blood coagulation factors in Korean male workers. J. Occup. Environ. Med. 2002, 44 (11), 997-1002.
[442]	Kim, K. J.; Yang, W. S.; Kim, S. B.; Lee, S. K.; Park, J. S., Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit. Dial. Int. 1997, 17 (2), 157-61.
[443]	Koenig, W.; Rothenbacher, D.; Hoffmeister, A.; Griesshammer, M.; Brenner, H., Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler. Thromb. Vasc. Biol. 2001, 21 (10), 1701-5.
[444]	Koenig, W., Fibrin(ogen) in cardiovascular disease: an update. Thromb. Haemost. 2003, 89 (4), 601-9.
[445]	Kullo, I. J.; Gau, G. T.; Tajik, A. J., Novel risk factors for atherosclerosis. Mayo Clin. Proc. 2000, 75 (4), 369-80.
[446]	Mori, Y.; Wada, H.; Nagano, Y.; Deguchi, K.; Kita, T.; Shirakawa, S., Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation. Thromb. Haemost. 1989, 61 (1), 140-3.
[447]	London, G. M.; Marchais, S. J.; Guerin, A. P.; Pannier, B., Arterial stiffness: pathophysiology and clinical impact. Clin. Exp. Hypertens. 2004, 26 (7-8), 689-99.
[448]	Meiselman, H. J., Hemorheologic alterations in hypertension: chicken or egg? Clin. Hemorheol. Microcirc. 1999, 21 (3-4), 195-200.
[449]	Prandoni, P.; Bilora, F.; Marchiori, A.; Bernardi, E.; Petrobelli, F.; Lensing, A. W.; Prins, M. H.; Girolami, A., An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 2003, 348 (15), 1435-41.
[450]	Reich, D. L.; Bennett-Guerrero, E.; Bodian, C. A.; Hossain, S.; Winfree, W.; Krol, M., Intraoperative tachycardia and hypertension are independently associated with adverse outcome in noncardiac surgery of long duration. Anesth. Analg. 2002, 95 (2), 273-7, table of contents.
[451]	Rudnicka, A. R.; Mt-Isa, S.; Meade, T. W., Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost 2006, 4 (11), 2405-10.
[452]	Puckett, L. G.; Barrett, G.; Kouzoudis, D.; Grimes, C.; Bachas, L. G., Monitoring blood coagulation with magnetoelastic sensors. Biosens. Bioelectron. 2003, 18 (5-6), 675-81.
[453]	Tavel, M. E.; Faris, J.; Nasser, W. K.; Feigebaum, H.; Fisch, C., Korotkoff sounds. Observations on pressure-pulse changes underlying their formation. Circulation 1969, 39 (4), 465-74.
[454]	Gleick, J., Chaos: Making a New Science 1988.
[455]	Biais, M.; Nouette-Gaulain, K.; Cottenceau, V.; Vallet, A.; Cochard, J. F.; Revel, P.; Sztark, F., Cardiac output measurement in patients undergoing liver transplantation: pulmonary artery catheter versus uncalibrated arterial pressure waveform analysis. Anesth. Analg. 2008, 106 (5), 1480-6, table of contents.
[456]	Rim, S. J.; Leong-Poi, H.; Lindner, J. R.; Wei, K.; Fisher, N. G.; Kaul, S., Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 2001, 104 (22), 2704-9.
[457]	Dintenfass, L., Some Observations on the Viscosity of Pathological Human Blood Plasma. Thromb. Diath. Haemorrh. 1965, 13, 492-9.
[458]	Bennett, A. F., Gleeson, Todd T., Gorman, George C., Anaerobic metabolism in a lizard (Anolis bonairensis) under natural conditions. Physiol. Zool. 1981, 54 (2), 237-241.
[459]	Dirkmann, D.; Hanke, A. A.; Gorlinger, K.; Peters, J., Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth. Analg. 2008, 106 (6), 1627-32.
[460]	Hardy, J. F.; De Moerloose, P.; Samama, M., Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can. J. Anaesth. 2004, 51 (4), 293-310.
[461]	Barnhart, M. I., Platelet responses in health and disease. Mol. Cell. Biochem. 1978, 22 (2-3), 113-37.
[462]	Tangelder, G. J.; Teirlinck, H. C.; Slaaf, D. W.; Reneman, R. S., Distribution of blood platelets flowing in arterioles. Am. J. Physiol. 1985, 248 (3 Pt 2), H318-23.
[463]	van Gelder, J. M.; Nair, C. H.; Dhall, D. P., The significance of red cell surface area to the permeability of fibrin network. Biorheology 1994, 31 (3), 259-75.
[464]	Schramm, W.; Schaarschmidt, K.; Schmidtler, F.; Schildberg, F. W., [The pathogenesis of postoperative abdominal wound dehiscence. Part II: Hemostasiological checks during the course in selected patient groups (author's transl)]. MMW. Munch. Med. Wochenschr. 1977, 119 (20), 690-4.
[465]	Scott, B. H., Opioids in cardiac surgery: cardiopulmonary bypass and inflammatory response. Int. J. Cardiol. 1998, 64 Suppl 1, S35-41.
[466]	Xia, X.; Batra, N.; Shi, Q.; Bonewald, L. F.; Sprague, E.; Jiang, J. X., Prostaglandin promotion of osteocyte gap junction function through transcriptional regulation of connexin 43 by glycogen synthase kinase 3/beta-catenin signaling. Mol. Cell. Biol. 2010, 30 (1), 206-19.
[467]	Nakase, T.; Fushiki, S.; Naus, C. C., Astrocytic gap junctions composed of connexin 43 reduce apoptotic neuronal damage in cerebral ischemia. Stroke 2003, 34 (8), 1987-93.
[468]	Kenny, L. C.; Baker, P. N.; Kendall, D. A.; Randall, M. D.; Dunn, W. R., The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br. J. Pharmacol. 2002, 136 (8), 1085-8.
[469]	Hu, V. W.; Xie, H. Q., Interleukin-1 alpha suppresses gap junction-mediated intercellular communication in human endothelial cells. Exp. Cell Res. 1994, 213 (1), 218-23.
[470]	Henson, J. H.; Nazarian, R.; Schulberg, K. L.; Trabosh, V. A.; Kolnik, S. E.; Burns, A. R.; McPartland, K. J., Wound closure in the lamellipodia of single cells: mediation by actin polymerization in the absence of an actomyosin purse string. Mol. Biol. Cell 2002, 13 (3), 1001-14.
[471]	Sersa, I.; Tratar, G.; Mikac, U.; Blinc, A., A mathematical model for the dissolution of non-occlusive blood clots in fast tangential blood flow. Biorheology 2007, 44 (1), 1-16.
[472]	Hahnenkamp, K.; Theilmeier, G.; Van Aken, H. K.; Hoenemann, C. W., The effects of local anesthetics on perioperative coagulation, inflammation, and microcirculation. Anesth. Analg. 2002, 94 (6), 1441-7.
[473]	Melzack, R.; Wall, P. D., Pain mechanisms: a new theory. Science 1965, 150 (699), 971-9.
[474]	Bromage, P. R., 50 Years on the wrong side of the reflex arc. Reg. Anesth. 1996, 21 (6 Suppl), 1-4.
[475]	Breslow, M. J.; Parker, S. D.; Frank, S. M.; Norris, E. J.; Yates, H.; Raff, H.; Rock, P.; Christopherson, R.; Rosenfeld, B. A.; Beattie, C., Determinants of catecholamine and cortisol responses to lower extremity revascularization. The PIRAT Study Group. Anesthesiology 1993, 79 (6), 1202-9.
[476]	Groban, L.; Vernon, J. C.; Butterworth, J., Intrathecal morphine reduces infarct size in a rat model of ischemia-reperfusion injury. Anesth. Analg. 2004, 98 (4), 903-9, table of contents.
[477]	Groeben, H.; Schwalen, A.; Irsfeld, S.; Tarnow, J.; Lipfert, P.; Hopf, H. B., High thoracic epidural anesthesia does not alter airway resistance and attenuates the response to an inhalational provocation test in patients with bronchial hyperreactivity. Anesthesiology 1994, 81 (4), 868-74.
[478]	Groudine, S. B.; Fisher, H. A.; Kaufman, R. P., Jr.; Patel, M. K.; Wilkins, L. J.; Mehta, S. A.; Lumb, P. D., Intravenous lidocaine speeds the return of bowel function, de-creases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth. Analg. 1998, 86 (2), 235-9.
[479]	Kuitunen, A.; Hynynen, M.; Salmenpera, M.; Rasi, V.; Jarvinen, A.; Scheinin, M.; Neuvonen, P. J.; Fyhrquist, F., Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. Br. J. Anaesth. 1993, 70 (2), 173-80.
[480]	Wickipedia. Autonomic Dysreflexia & Hyperreflexia. http://www.apparelyzed.com/autonomic.html.
[481]	Yeager, M. P.; Glass, D. D.; Neff, R. K.; Brinck-Johnsen, T., Epidural anesthesia and analgesia in high-risk surgical patients by preventing nociception that activates the capillary gate component via the spinal pathway. Anesthesiology 1987, 66 (6), 729-36.
[482]	Zhang, J.; Zhang, W.; Li, B., The effect of epidural anesthesia with different concentrations of ropivacaine on se-voflurane requirements. Anesth. Analg. 2007, 104 (4), 984-6.
[483]	Yoo, K.; Hwang, J.; Jeong, S.; Kim, S.; Bae, H.; Choi, J.; Chung, S.; Lee, J., Anesthetic requirements and stress hormone responses in spinal cord-injured patients undergoing surgery below the level of injury. Anesth. Analg. 2006, 102 (4), 1223-8.
[484]	Christopherson, R.; Beattie, C.; Frank, S. M.; Norris, E. J.; Meinert, C. L.; Gottlieb, S. O.; Yates, H.; Rock, P.; Parker, S. D.; Perler, B. A., Perioperative morbidity in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology 1993, 79 (3), 422-34.
[485]	Christopherson, R.; Glavan, N. J.; Norris, E. J.; Beattie, C.; Rock, P.; Frank, S. M.; Gottlieb, S. O., Control of blood pressure and heart rate in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial (PIRAT) Study Group. J. Clin. Anesth. 1996, 8 (7), 578-84.
[486]	Davis, R. F.; DeBoer, L. W.; Maroko, P. R., Thoracic epidural anesthesia reduces myocardial infarct size after coronary artery occlusion in dogs. Anesth. Analg. 1986, 65 (7), 711-7.
[487]	Exadaktylos, A. K.; Buggy, D. J.; Moriarty, D. C.; Mascha, E.; Sessler, D. I., Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthe-siology 2006, 105 (4), 660-4.
[488]	Filimonovic, J.; Gvozdic, B.; Krivic, B.; Acimovic, M.; Tulic, C.; Hadzi Djokic, J., Anesthesia for radical prostatectomy. Acta Chir. Iugosl. 2005, 52 (4), 113-7.
[489]	Giesecke, K.; Hamberger, B.; Jarnberg, P. O.; Klingstedt, C.; Persson, B., High- and low-dose fentanyl anaesthesia: hormonal and metabolic responses during cholecystectomy. Br. J. Anaesth. 1988, 61 (5), 575-82.
[490]	Modig, J.; Borg, T.; Karlstrom, G.; Maripuu, E.; Sahlstedt, B., Thromboembolism after total hip replacement: role of epidural and general anesthesia. Anesth. Analg. 1983, 62 (2), 174-80.
[491]	Modig, J.; Borg, T.; Bagge, L.; Saldeen, T., Role of extradural and of general anaesthesia in fibrinolysis and coagulation after total hip replacement. Br. J. Anaesth. 1983, 55 (7), 625-9.
[492]	Modig, J., The role of lumbar epidural anaesthesia as antithrombotic prophylaxis in total hip replacement. Acta Chir. Scand. 1985, 151 (7), 589-94.
[493]	Moore, C. M.; Cross, M. H.; Desborough, J. P.; Burrin, J. M.; Macdonald, I. A.; Hall, G. M., Hormonal effects of thoracic extradural analgesia for cardiac surgery. Br. J. Anaesth. 1995, 75 (4), 387-93.
[494]	Pflug, A. E.; Halter, J. B., Effect of spinal anesthesia on adrenergic tone and the neuroendocrine responses to surgical stress in humans. Anesthesiology 1981, 55 (2), 120-6.
[495]	Rodgers, A.; Walker, N.; Schug, S.; McKee, A.; Kehlet, H.; van Zundert, A.; Sage, D.; Futter, M.; Saville, G.; Clark, T.; MacMahon, S., Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000, 321 (7275), 1493.
[496]	Roizen, M. F., Should we all have a sympathectomy at birth? Or at least preoperatively? Anesthesiology 1988, 68 (4), 482-4.
[497]	Rosenfeld, B. A.; Beattie, C.; Christopherson, R.; Norris, E. J.; Frank, S. M.; Breslow, M. J.; Rock, P.; Parker, S. D.; Gottlieb, S. O.; Perler, B. A., The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology 1993, 79 (3), 435-43.
[498]	Sebel, P. S.; Bovil, J. G., Cardiovascular effects of sufentanil anesthesia. Anesth. Analg. 1982, 61 (2), 115-9.
[499]	Treschan, T. A.; Taguchi, A.; Ali, S. Z.; Sharma, N.; Kabon, B.; Sessler, D. I.; Kurz, A., The effects of epidural and general anesthesia on tissue oxygenation. Anesth. Analg. 2003, 96 (6), 1553-7, table of contents.
[500]	Tverskoy, M.; Gelman, S.; Fowler, K. C.; Bradley, E. L., Influence of fentanyl and morphine on intestinal circulation. Anesth. Analg. 1985, 64 (6), 577-84.
[501]	Tverskoy, M.; Cozacov, C.; Ayache, M.; Bradley, E. L., Jr.; Kissin, I., Postoperative pain after inguinal herniorrhaphy with different types of anesthesia. Anesth. Analg. 1990, 70 (1), 29-35.
[502]	Woolf, C. J.; Chong, M. S., Preemptive analgesia--treating postoperative pain by preventing the estab-lishment of central sensitization. Anesth. Analg. 1993, 77 (2), 362-79.
[503]	Woolf, C. J., Evidence for a central component of post-injury pain hypersensitivity. Nature 1983, 306 (5944), 686-8.
[504]	Woolf, C. J.; Wall, P. D., Morphine-sensitive and morphine-insensitive actions of C-fibre input on the rat spinal cord. Neurosci. Lett. 1986, 64 (2), 221-5.
[505]	Anand, K. J.; Sippell, W. G.; Aynsley-Green, A., Randomised trial of fentanyl anaesthesia in preterm babies undergoing surgery: effects on the stress response. Lancet 1987, 1 (8524), 62-6.
[506]	Anand, K. J.; Hickey, P. R., Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. N. Engl. J. Med. 1992, 326 (1), 1-9.
[507]	Anand, K. J.; Hansen, D. D.; Hickey, P. R., Hormonal-metabolic stress responses in neonates undergoing cardiac surgery. Anesthesiology 1990, 73 (4), 661-70.
[508]	Edde, R. R., Hemodynamic changes prior to and after sternotomy in patients anesthetized with high-dose fentanyl. Anesthesiology 1981, 55 (4), 444-6.
[509]	Fisk, N. M.; Gitau, R.; Teixeira, J. M.; Giannakoulopoulos, X.; Cameron, A. D.; Glover, V. A., Effect of direct fetal opioid analgesia on fetal hormonal and hemodynamic stress response to intrauterine needling. Anesthesiology 2001, 95 (4), 828-35.
[510]	Hickey, P. R.; Hansen, D. D., High-dose fentanyl reduces intraoperative ventricular fibrillation in neonates with hypoplastic left heart syndrome. J. Clin. Anesth. 1991, 3 (4), 295-300.
[511]	Khomulo, P. S.; Dmitrieva, N. A.; Eliner, G. I., [Atherosclerosis in rabbits induced by prolonged electrical stimulation of the hypothalamus]. Biull. Eksp. Biol. Med. 1976, 82 (11), 1294-6.
[512]	Khomulo, P. S.; Ambrozas, I. V.; Dmitrieva, N. A.; Zharova, I. P.; Nikolaev, V. I., [Development of atherosclerosis in alternating prolonged electrostimulation of the negative and positive hypothalamic emotiogenic zones]. Kardiologiia 1980, 20 (3), 104-8.
[513]	Gutstein, W. H.; Parl, F., Neural factors in experimental degenerative arteriopathy. Lipids 1978, 13 (5), 380-2.
[514]	Gutstein, W. H.; Harrison, J.; Parl, F.; Ku, G.; Avtable, M., Neural factors contribute to atherogenesis. Science 1978, 199 (4327), 449-51.
[515]	Parker, E. S.; Cahill, L.; McGaugh, J. L., A case of unusual autobiographical remembering. Neurocase 2006, 12 (1), 35-49.
[516]	Price, J., The Woman Who Can't Forget: The Extraordinary Story of Living with the Most Remarkable Memory Known to Science-A Memoir. Free Press, a division of Simon and Schuster: 2008; p 263.
[517]	Wickipedia. Hyperthymestic Syndrome. http://en.wikipedia.org/wiki/Hyperthymesia.
[518]	Hobson, J. A., Dreaming as delirium: a mental status analysis of our nightly madness. Semin. Neurol. 1997, 17 (2), 121-8.
[519]	Chapman, C. R.; Tuckett, R. P.; Song, C. W., Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain 2008, 9 (2), 122-45.
[520]	Jern, C.; Eriksson, E.; Tengborn, L.; Risberg, B.; Wadenvik, H.; Jern, S., Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb. Haemost. 1989, 62 (2), 767-71.
[521]	Feigl, E. O.; Buffington, C. W.; Nathan, H. J., Adrenergic coronary vasoconstriction during myocardial underperfusion. Circulation 1987, 75 (1 Pt 2), I1-5.
[522]	Freeman, L. J.; Nixon, P. G.; Sallabank, P.; Reaveley, D., Psychological stress and silent myocardial ischemia. Am. Heart J. 1987, 114 (3), 477-82.
[523]	Sano, H.; Itoh, H., [Idiopathic insomnia]. Nippon Rinsho. 1998, 56 (2), 361-4.
[524]	Wong, K. C., Narcotics are not expected to produce unconsciousness and amnesia. Anesth. Analg. 1983, 62 (7), 625-6.
[525]	Bovill, J. G.; Sebel, P. S.; Stanley, T. H., Opioid analgesics in anesthesia: with special reference to their use in cardiovascular anesthesia. Anesthesiology 1984, 61 (6), 731-55.
[526]	Bovill, J. G.; Sebel, P. S.; Fiolet, J. W.; Touber, J. L.; Kok, K.; Philbin, D. M., The influence of sufentanil on endocrine and metabolic responses to cardiac surgery. Anesth. Analg. 1983, 62 (4), 391-7.
[527]	Behar, M. Can Fear Be Forgotten Popular Science [Online], 2007. http://www.popsci.com/scitech/article/2007-12/can-fear-be-forgotten.
[528]	Dorges, V.; Wenzel, V.; Dix, S.; Kuhl, A.; Schumann, T.; Huppe, M.; Iven, H.; Gerlach, K., The effect of midazolam on stress levels during simulated emergency medical service transport: a placebo-controlled, dose-response study. Anesth. Analg. 2002, 95 (2), 417-22, table of contents.
[529]	Mukamal, K. J.; Cushman, M.; Mittleman, M. A.; Tracy, R. P.; Siscovick, D. S., Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study. Atherosclerosis 2004, 173 (1), 79-87.
[530]	Hoffmeister, A.; Imhof, A.; Rothenbacher, D.; Khuseyinova, N.; Brenner, H.; Koenig, W., [Moderate alcohol consumption and plasma concentration of sensitive markers of inflammation. Comment on an atheroprotective relationship]. Dtsch. Med. Wochenschr. 2003, 128 (43), 2237-41.
[531]	Wannamethee, S. G.; Lowe, G. D.; Shaper, G.; Whincup, P. H.; Rumley, A.; Walker, M.; Lennon, L., The effects of different alcoholic drinks on lipids, insulin and haemostatic and inflammatory markers in older men. Thromb. Haemost. 2003, 90 (6), 1080-7.
[532]	Mangano, D. T.; Siliciano, D.; Hollenberg, M.; Leung, J. M.; Browner, W. S.; Goehner, P.; Merrick, S.; Verrier, E., Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group. Anesthesiology 1992, 76 (3), 342-53.
[533]	Myles, P. S.; Hunt, J. O.; Fletcher, H.; Watts, J.; Bain, D.; Silvers, A.; Buckland, M. R., Remifentanil, fentanyl, and cardiac surgery: a double-blinded, randomized, controlled trial of costs and outcomes. Anesth. Analg. 2002, 95 (4), 805-12, table of contents.
[534]	Kario, K.; Matsuo, T.; Kobayashi, H.; Yamamoto, K.; Shimada, K., Earthquake-induced potentiation of acute risk factors in hypertensive elderly patients: possible triggering of cardiovascular events after a major earthquake. J. Am. Coll. Cardiol. 1997, 29 (5), 926-33.
[535]	Kario, K.; Matsuo, T.; Kobayashi, H.; Matsuo, M.; Sakata, T.; Miyata, T.; Shimada, K., Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler. Thromb. Vasc. Biol. 1996, 16 (3), 455-61.
[536]	Kario, K.; Matsuo, T.; Kayaba, K.; Soukejima, S.; Kagamimori, S.; Shimada, K., Earthquake-induced cardiovas-cular disease and related risk factors in focusing on the Great Hanshin-Awaji Earthquake. J. Epidemiol. 1998, 8 (3), 131-9.
[537]	Kario, K.; Matsuo, T., Increased incidence of cardiovascular attacks in the epicenter just after the Han-shin-Awaji earthquake. Thromb. Haemost. 1995, 74 (4), 1207.
[538]	Matsuo, T.; Suzuki, S.; Kodama, K.; Kario, K., Hemostatic activation and cardiac events after the 1995 Hanshin-Awaji earthquake. Int. J. Hematol. 1998, 67 (2), 123-9.
[539]	Matsuo, T.; Suzuki, S.; Kario, K.; Kobayashi, H., [Acute myocardial infarction in the 1995 Hanshin-Awaji Earthquake]. Rinsho Byori. 1997, Suppl 104, 133-41.
[540]	Matsuo, T.; Kobayashi, H.; Kario, K.; Suzuki, S.; Matsuo, M., [Role of biochemical and fibrinolytic parameters on cardiac events associated with Hanshin-Awaji earthquake-induced stress]. Rinsho Byori. 1998, 46 (6), 593-8.
[541]	Pignalberi, C.; Ricci, R.; Santini, M., [Psychological stress and sudden death]. Ital Heart J 2002, 3 (10 Suppl), 1011-21.
[542]	von Kanel, R.; Hepp, U.; Buddeberg, C.; Keel, M.; Mica, L.; Aschbacher, K.; Schnyder, U., Altered blood coagulation in patients with posttraumatic stress disorder. Psychosom. Med. 2006, 68 (4), 598-604.
[543]	Hao, Z.; Jiang, X.; Sharafeih, R.; Shen, S.; Hand, A. R.; Cone, R. E.; O'Rourke, J., Stimulated release of tissue plasminogen activator from artery wall sympathetic nerves: implications for stress-associated wall damage. Stress 2005, 8 (2), 141-9.
[544]	Ranjbar, F.; Akbarzadeh, F.; Kazemi, K.; Safaeiyan, A., Relaxation therapy in the background of standard antihypertensive drug treatment is effective in management of moderate to severe essential hypertension. Saudi Med J 2007, 28 (9), 1353-6.
[545]	Landesberg, G.; Mosseri, M.; Zahger, D.; Wolf, Y.; Perouansky, M.; Anner, H.; Drenger, B.; Hasin, Y.; Berlatzky, Y.; Weissman, C., Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia. J. Am. Coll. Cardiol. 2001, 37 (7), 1839-45.
[546]	Mangano, D. T.; Hollenberg, M.; Fegert, G.; Meyer, M. L.; London, M. J.; Tubau, J. F.; Krupski, W. C., Perioperative myocardial ischemia in patients undergoing noncardiac surgery-I: Incidence and severity during the 4 day perioperative period. The Study of Perioperative Ischemia (SPI) Research Group. J. Am. Coll. Cardiol. 1991, 17 (4), 843-50.
[547]	Fornek, J. L.; Korth, M. J.; Katze, M. G., Use of functional genomics to understand influenza-host interactions. Adv. Virus Res. 2007, 70, 81-100.
[548]	Kipnis, E.; Guery, B. P.; Tournoys, A.; Leroy, X.; Robriquet, L.; Fialdes, P.; Neviere, R.; Fourrier, F., Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 2004, 21 (5), 444-51.
[549]	Bonacci, J. V.; Harris, T.; Wilson, J. W.; Stewart, A. G., Collagen-induced resistance to glucocorticoid anti-mitogenic actions: a potential explanation of smooth muscle hyperplasia in the asthmatic remodelled airway. Br. J. Pharmacol. 2003, 138 (7), 1203-6.
[550]	Hesselvik, J. F.; Blomback, M.; Brodin, B.; Maller, R., Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit. Care Med. 1989, 17 (8), 724-33.
[551]	Healy, D. P., New and emerging therapies for sepsis. Ann. Pharmacother. 2002, 36 (4), 648-54.
[552]	Warr, T. A.; Rao, L. V.; Rapaport, S. I., Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990, 75 (7), 1481-9.
[553]	Angelov, A., [Intravascular coagulation in amniotic fluid embolism]. Akush. Ginekol. (Sofiia). 1989, 28 (5), 24-9.
[554]	Lau, G.; Chui, P. P., Amniotic fluid embolism: a review of 10 fatal cases. Singapore Med. J. 1994, 35 (2), 180-3.
[555]	Lockwood, C. J.; Bach, R.; Guha, A.; Zhou, X. D.; Miller, W. A.; Nemerson, Y., Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am. J. Obstet. Gynecol. 1991, 165 (5 Pt 1), 1335-41.
[556]	Modesti, P. A.; Gamberi, T.; Bazzini, C.; Borro, M.; Romano, S. M.; Cambi, G. E.; Corvi, A.; Dorigo, W.; Paparella, L.; Pratesi, C.; Carini, M.; Gensini, G.; Modesti, A., Response of Serum Proteome in Patients Undergoing Infrarenal Aortic Aneurysm Repair. Anesthesiology 2009.
[557]	Adembri, C.; Kastamoniti, E.; Bertolozzi, I.; Vanni, S.; Dorigo, W.; Coppo, M.; Pratesi, C.; De Gaudio, A. R.; Gensini, G. F.; Modesti, P. A., Pulmonary injury follows systemic inflammatory reaction in infrarenal aortic sur-gery. Crit. Care Med. 2004, 32 (5), 1170-7.
[558]	Garvin, S.; Muehlschlegel, J. D.; Perry, T. E.; Chen, J.; Liu, K. Y.; Fox, A. A.; Collard, C. D.; Aranki, S. F.; Shernan, S. K.; Body, S. C., Postoperative Activity, but Not Preoperative Activity, of Antithrombin Is Associated with Major Adverse Cardiac Events After Coronary Artery Bypass Graft Surgery. Anesth. Analg. 2009.
[559]	Herrero, J. F.; Laird, J. M.; Lopez-Garcia, J. A., Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog. Neurobiol. 2000, 61 (2), 169-203.
[560]	Coderre, T. J.; Melzack, R., Cutaneous hyperalgesia: contributions of the peripheral and central nervous systems to the increase in pain sensitivity after injury. Brain Res. 1987, 404 (1-2), 95-106.
[561]	Cousins, M. J., John J. Bonica distinguished lecture. Acute pain and the injury response: immediate and prolonged effects. Reg. Anesth. 1989, 14 (4), 162-79.
[562]	Ofek, H.; Defrin, R., The characteristics of chronic central pain after traumatic brain injury. Pain 2007.
[563]	Wall, P. D.; Woolf, C. J., The brief and the prolonged facilitatory effects of unmyelinated afferent input on the rat spinal cord are independently influenced by peripheral nerve section. Neuroscience 1986, 17 (4), 1199-205.
[564]	Baum, M.; Demicheli, R.; Hrushesky, W.; Retsky, M., Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? Eur. J. Cancer 2005, 41 (4), 508-15.
[565]	Berglund, U.; Wallentin, L.; von Schenck, H., Platelet function and plasma fibrinogen and their relations to gender, smoking habits, obesity and beta-blocker treatment in young survivors of myocardial infarction. Thromb. Haemost. 1988, 60 (1), 21-4.
[566]	Inoue, K.; Takano, H.; Yanagisawa, R.; Sakurai, M.; Yoshikawa, T., Surgical stress in ARDS open-lung biopsy. Chest 2004, 126 (4), 1383-4; author reply 1384.
[567]	Abraham, E., Physiologic stress and cellular ischemia: relationship to immunosuppression and susceptibility to sepsis. Crit. Care Med. 1991, 19 (5), 613-8.
[568]	Avikainen, V., Coagulation disorders in severely and critically injured patients. Ann. Chir. Gynaecol. 1977, 66 (6), 269-77.
[569]	Sielenkamper, A. W.; Meyer, J.; Kloppenburg, H.; Eicker, K.; Van Aken, H., The effects of sepsis on gut mucosal blood flow in rats. Eur. J. Anaesthesiol. 2001, 18 (10), 673-8.
[570]	Garrison, R. N.; Spain, D. A.; Wilson, M. A.; Keelen, P. A.; Harris, P. D., Microvascular changes explain the "two-hit" theory of multiple organ failure. Ann. Surg. 1998, 227 (6), 851-60.
[571]	Weijer, S.; Schoenmakers, S. H.; Florquin, S.; Levi, M.; Vlasuk, G. P.; Rote, W. E.; Reitsma, P. H.; Spek, C. A.; van der Poll, T., Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J. Infect. Dis. 2004, 189 (12), 2308-17.
[572]	Wei, S. J., [The assessment of factor VIII-related antigen in endothelial cells of pulmonary blood vessels in multiple organ failure]. Zhonghua Jie He He Hu Xi Za Zhi 1990, 13 (6), 346-8, 380.
[573]	Moalli, R.; Doyle, J. M.; Tahhan, H. R.; Hasan, F. M.; Braman, S. S.; Saldeen, T., Fibrinolysis in critically ill patients. Am. Rev. Respir. Dis. 1989, 140 (2), 287-93.
[574]	Modig, J.; Borg, T.; Wegenius, G.; Bagge, L.; Saldeen, T., The value of variables of disseminated intravascular coagulation in the diagnosis of adult respiratory distress syndrome. Acta Anaesthesiol. Scand. 1983, 27 (5), 369-75.
[575]	Rubin, D. B.; Wiener-Kronish, J. P.; Murray, J. F.; Green, D. R.; Turner, J.; Luce, J. M.; Montgomery, A. B.; Marks, J. D.; Matthay, M. A., Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J. Clin. Invest. 1990, 86 (2), 474-80.
[576]	Draheim, C. C.; McCubbin, J. A.; Williams, D. P., Differences in cardiovascular disease risk between nondiabetic adults with mental retardation with and without Down syndrome. Am. J. Ment. Retard. 2002, 107 (3), 201-11.
[577]	Draheim, C. C.; Geijer, J. R.; Dengel, D. R., Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome. Am. J. Cardiol. 2010, 106 (10), 1512-6.
[578]	Bilora, F.; Boccioletti, V.; Zanon, E.; Petrobelli, F.; Girolami, A., Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost 2001, 7 (4), 311-3.
[579]	Wang, X.; Wang, E.; Kavanagh, J. J.; Freedman, R. S., Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005, 3, 25.
[580]	von Tempelhoff, G. F.; Schonmann, N.; Heilmann, L., Thrombosis-a clue of poor prognosis in primary non-metastatic breast cancer? Breast Cancer Res. Treat. 2002, 73 (3), 275-7.
[581]	von Tempelhoff, G. F.; Nieman, F.; Heilmann, L.; Hommel, G., Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin. Hemorheol. Microcirc. 2000, 22 (2), 107-30.
[582]	H. Leon Bradlow, J. F. a. M. P. O., Cancer: Genetics and the Environment. New York Academy of Sciences: 1997; Vol. 833, p 209.
[583]	Bhatia, S.; Robison, L. L.; Oberlin, O.; Greenberg, M.; Bunin, G.; Fossati-Bellani, F.; Meadows, A. T., Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. 1996, 334 (12), 745-51.
[584]	Jee, S. H.; Ohrr, H.; Sull, J. W.; Yun, J. E.; Ji, M.; Samet, J. M., Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293 (2), 194-202.
[585]	Coussens, L. M.; Werb, Z., Inflammation and cancer. Nature 2002, 420 (6917), 860-7.
[586]	Elikowski, W.; Maka, K.; Bol, K.; Jedlinski, I.; Kubaszewska, M., [Multifocal ischaemic stroke and myocardial infarction in a woman with occult lung cancer complicated with chronic DIC and thrombotic endocarditis]. Neurol. Neurochir. Pol. 2006, 40 (6), 530-5.
[587]	Fitzgerald, R. H., Jr., Laboratory diagnosis of postoperative sepsis of the musculoskeletal system. Orthop. Clin. North Am. 1979, 10 (2), 361-74.
[588]	McCoy, G. D.; Wynder, E. L., Etiological and preventive implications in alcohol carcinogenesis. Cancer Res. 1979, 39 (7 Pt 2), 2844-50.
[589]	Pankhurst, T.; Savage, C. O.; Gordon, C.; Harper, L., Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004.
[590]	Sala-Serra, M.; Sunyer, J.; Kogevinas, M.; McFarlane, D.; Anto, J. M., Cohort study on cancer mortality among workers in the pulp and paper industry in Catalonia, Spain. Am. J. Ind. Med. 1996, 30 (1), 87-92.
[591]	Smedby, K. E.; Baecklund, E.; Askling, J., Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol. Biomarkers Prev. 2006, 15 (11), 2069-77.
[592]	Davis, D., The Secret History of the War on Cancer. Perseus Books Group: New York, N.Y., 2007.
[593]	Levi, M.; van der Poll, T.; Ten Cate, H., Tissue factor in infection and severe inflammation. Semin. Thromb. Hemost. 2006, 32 (1), 33-9.
[594]	Asanuma, K.; Wakabayashi, H.; Hayashi, T.; Okuyama, N.; Seto, M.; Matsumine, A.; Kusuzaki, K.; Suzuki, K.; Uchida, A., Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology 2004, 67 (2), 166-73.
[595]	Bobek, V.; Kovarik, J., Antitumor and antimetastatic effect of warfarin and heparins. Biomed. Pharmacother. 2004, 58 (4), 213-9.
[596]	Cao, Q. Z.; Niu, G.; Tan, H. R., In vitro growth inhibition of human colonic tumor cells by Verapamil. World J Gastroenterol 2005, 11 (15), 2255-9.
[597]	Holzheimer, R. G., Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur. J. Med. Res. 2004, 9 (4), 225-39.
[598]	Hampton, K. K.; Grant, P. J.; Primrose, J.; Dean, H. G.; Davies, J. A.; Prentice, C. R., Haemostatic responses and vasopressin release during colonoscopy in man. Clin Sci (Lond) 1991, 81 (2), 257-60.
[599]	Samama, C. M.; Thiry, D.; Elalamy, I.; Diaby, M.; Guillosson, J. J.; Kieffer, E.; Coriat, P., Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 2001, 94 (1), 74-8.
[600]	Weissman, C., The metabolic response to stress: an overview and update. Anesthesiology 1990, 73 (2), 308-27.
[601]	Monk, T. G.; Saini, V.; Weldon, B. C.; Sigl, J. C., Anesthetic management and one-year mortality after noncardiac surgery. Anesth. Analg. 2005, 100 (1), 4-10.
[602]	Liberzon, I.; Abelson, J. L.; Amdur, R. L.; King, A. P.; Cardneau, J. D.; Henke, P.; Graham, L. M., Increased psychiatric morbidity after abdominal aortic surgery: risk factors for stress-related disorders. J. Vasc. Surg. 2006, 43 (5), 929-34.
[603]	Chernow, B.; Alexander, H. R.; Smallridge, R. C.; Thompson, W. R.; Cook, D.; Beardsley, D.; Fink, M. P.; Lake, C. R.; Fletcher, J. R., Hormonal responses to graded surgical stress. Arch. Intern. Med. 1987, 147 (7), 1273-8.
[604]	Kavarana, M. N.; Frumento, R. J.; Hirsch, A. L.; Oz, M. C.; Lee, D. C.; Bennett-Guerrero, E., Gastric hypercarbia and adverse outcome after cardiac surgery. Intensive Care Med. 2003, 29 (5), 742-8.
[605]	McDaniel, M. D.; Pearce, W. H.; Yao, J. S.; Rossi, E. C.; Fahey, V. A.; Green, D.; Flinn, W. R.; Bergan, J. J., Sequential changes in coagulation and platelet function following femorotibial bypass. J. Vasc. Surg. 1984, 1 (2), 261-8.
[606]	Abram, S. E.; Yaksh, T. L., Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. Anesthesiology 1994, 80 (2), 383-91; discussion 25A.
[607]	Abram, S. E.; Yaksh, T. L., Morphine, but not inhalation anesthesia, blocks post-injury facilitation. The role of preemptive suppression of afferent transmission. Anesthesiology 1993, 78 (4), 713-21.
[608]	Eliopoulos, A. G.; Kerr, D. J.; Herod, J.; Hodgkins, L.; Krajewski, S.; Reed, J. C.; Young, L. S., The control of apoptosis and drug resistance in ovarian cancer: influ-ence of p53 and Bcl-2. Oncogene 1995, 11 (7), 1217-28.
[609]	Crile GW, L. W., Anoci-association. Saunders: Philadelphia, 1914; p 223-225.
[610]	Schneemilch, C. E.; Bank, U., [Release of pro- and anti-inflammatory cytokines during different anesthesia procedures]. Anaesthesiol. Reanim. 2001, 26 (1), 4-10.
[611]	Ben-Shlomo, I.; Finger, J.; Bar-Av, E.; Perl, A. Z.; Etchin, A.; Tverskoy, M., Propofol and fentanyl act additively for induction of anaesthesia. Anaesthesia 1993, 48 (2), 111-3.
[612]	Ben-Shlomo, I.; abd-el-Khalim, H.; Ezry, J.; Zohar, S.; Tverskoy, M., Midazolam acts synergistically with fentanyl for induction of anaesthesia. Br. J. Anaesth. 1990, 64 (1), 45-7.
[613]	Brunner, M. D.; Braithwaite, P.; Jhaveri, R.; McEwan, A. I.; Goodman, D. K.; Smith, L. R.; Glass, P. S., MAC reduction of isoflurane by sufentanil. Br. J. Anaesth. 1994, 72 (1), 42-6.
[614]	Beattie, W. S.; Badner, N. H.; Choi, P., Epidural analgesia reduces postoperative myocardial infarction: a meta-analysis. Anesth. Analg. 2001, 93 (4), 853-8.
[615]	Von Dossow, V.; Welte, M.; Zaune, U.; Martin, E.; Walter, M.; Ruckert, J.; Kox, W. J.; Spies, C. D., Thoracic epidural anesthesia combined with general anesthesia: the preferred anesthetic technique for thoracic surgery. Anesth. Analg. 2001, 92 (4), 848-54.
[616]	Vinik, H. R.; Bradley, E. L., Jr.; Kissin, I., Triple anesthetic combination: propofol-midazolam-alfentanil. Anesth. Analg. 1994, 78 (2), 354-8.
[617]	Negishi, C.; Kim, J. S.; Lenhardt, R.; Sessler, D. I.; Ozaki, M.; Vuong, K.; Bastanmehr, H.; Bjorksten, A. R., Alfentanil reduces the febrile response to interleukin-2 in humans. Crit. Care Med. 2000, 28 (5), 1295-300.
[618]	Dubois, M.; Pickar, D.; Cohen, M.; Gadde, P.; Macnamara, T. E.; Bunney, W. E., Effects of fentanyl on the response of plasma beta-endorphin immunoreactivity to surgery. Anesthesiology 1982, 57 (6), 468-72.
[619]	Glass, P. S.; Gan, T. J.; Howell, S.; Ginsberg, B., Drug interactions: volatile anesthetics and opioids. J. Clin. Anesth. 1997, 9 (6 Suppl), 18S-22S.
[620]	Hecker, B. R.; Lake, C. L.; DiFazio, C. A.; Mo-scicki, J. C.; Engle, J. S., The decrease of the minimum alveolar anesthetic concentration produced by sufentanil in rats. Anesth. Analg. 1983, 62 (11), 987-90.
[621]	Klassen, G. A.; Bramwell, R. S.; Bromage, P. R.; Zborowska-Sluis, D. T., Effect of acute sympathectomy by epidural anesthesia on the canine coronary circulation. Anesthesiology 1980, 52 (1), 8-15.
[622]	Kissin, I.; Vinik, H. R.; Castillo, R.; Bradley, E. L., Jr., Alfentanil potentiates midazolam-induced unconsciousness in subanalgesic doses. Anesth. Analg. 1990, 71 (1), 65-9.
[623]	Mallinder, P. A.; Hall, J. E.; Bergin, F. G.; Royle, P.; Leaper, D. J., A comparison of opiate- and epidural-induced alterations in splanchnic blood flow using intra-operative gastric tonometry. Anaesthesia 2000, 55 (7), 659-65.
[624]	Steffey, E. P.; Martucci, R.; Howland, D.; Asling, J. H.; Eisele, J. H., Meperidine-halothane interaction in dogs. Can. Anaesth. Soc. J. 1977, 24 (4), 459-67.
[625]	Pypendop, B. H.; Ilkiw, J. E., The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. Anesth. Analg. 2005, 100 (1), 97-101.
[626]	Rakaric-Poznanovic, M.; Ranic, V.; Snur, I., [Multiorgan dysfunction syndrome (MODS) caused by long bone fractures in young persons]. Lijec. Vjesn. 1995, 117 Suppl 2, 85-7.
[627]	Valverde, A.; Doherty, T. J.; Hernandez, J.; Davies, W., Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. Vet Anaesth Analg 2004, 31 (4), 264-71.
[628]	Zhang, Y.; Laster, M. J.; Eger, E. I., 2nd; Sharma, M.; Sonner, J. M., Lidocaine, MK-801, and MAC. Anesth. Analg. 2007, 104 (5), 1098-102, tables of contents.
[629]	Hall, R. I.; Szlam, F.; Hug, C. C., Jr., The enflurane-sparing effect of alfentanil in dogs. Anesth. Analg. 1987, 66 (12), 1287-91.
[630]	Haldemann, G.; Hossli, G.; Schaer, H., [Anaesthesia with flunitrazepam (rohypnol) and fentanyl for geriatric patients (author's transl)]. Anaesthesist 1977, 26 (4), 168-71.
[631]	Kabon, B.; Fleischmann, E.; Treschan, T.; Taguchi, A.; Kapral, S.; Kurz, A., Thoracic epidural anesthesia increases tissue oxygenation during major abdominal surgery. Anesth. Analg. 2003, 97 (6), 1812-7.
[632]	Kapral, S.; Gollmann, G.; Bachmann, D.; Prohaska, B.; Likar, R.; Jandrasits, O.; Weinstabl, C.; Lehofer, F., The effects of thoracic epidural anesthesia on intraoperative visceral perfusion and metabolism. Anesth. Analg. 1999, 88 (2), 402-6.
[633]	Kehlet, H.; Holte, K., Effect of postoperative analgesia on surgical outcome. Br. J. Anaesth. 2001, 87 (1), 62-72.
[634]	Kono, K.; Philbin, D. M.; Coggins, C. H.; Moss, J.; Rosow, C. E.; Schneider, R. C.; Slater, E. E., Renal function and stress response during halothane or fentanyl anesthesia. Anesth. Analg. 1981, 60 (8), 552-6.
[635]	Lee, T. W.; Grocott, H. P.; Schwinn, D.; Jacobsohn, E., High spinal anesthesia for cardiac surgery: effects on beta-adrenergic receptor function, stress response, and hemodynamics. Anesthesiology 2003, 98 (2), 499-510.
[636]	Lessa, M. A.; Tibirica, E., Pharmacologic evidence for the involvement of central and peripheral opioid receptors in the cardioprotective effects of fentanyl. Anesth. Analg. 2006, 103 (4), 815-21.
[637]	Lessa, M. A.; Rodrigues, E.; Tibirica, E., Cardioprotective action of fentanyl in a model of central sympathetic overactivity in rabbits: antiarrhythmic and anti-ischemic effects. Acta Anaesthesiol. Scand. 2004, 48 (9), 1115-22.
[638]	McEwan, A. I.; Smith, C.; Dyar, O.; Goodman, D.; Smith, L. R.; Glass, P. S., Isoflurane minimum alveolar concentration reduction by fentanyl. Anesthesiology 1993, 78 (5), 864-9.
[639]	Moffitt, E. A.; McIntyre, A. J.; Barker, R. A.; Imrie, D. D.; Murphy, D. A.; Landymore, R. W.; Kinley, C. E., Myocardial metabolism and hemodynamic responses with fentanyl-enflurane anesthesia for coronary arterial surgery. Anesth. Analg. 1986, 65 (1), 46-52.
[640]	Murphy, M. R.; Hug, C. C., Jr., The anesthetic potency of fentanyl in terms of its reduction of enflurane MAC. Anesthesiology 1982, 57 (6), 485-8.
[641]	O'Connor, T. C.; Abram, S. E., Halothane enhances suppression of spinal sensitization by intrathecal morphine in the rat formalin test. Anesthesiology 1994, 81 (5), 1277-83.
[642]	Raymond S. Sinatra, A. H. H., Brian Ginsburg, Linda M. Preble, Acute Pain Mechanisms and Management. Mosby Year-Book, Inc. : St. Louis, Missouri, 1972; p P. 49 of 636.
[643]	Rowlingson, J. C. In Update on Acute Pain Management, 80th Clinical and Scientific Congress of the International Anesthesia Research Society, Embarcadero Center, San Francisco, Ca. , 2006; International Anesthesia Research Society: Embarcadero Center, San Francisco, Ca. , 2006; p 137.
[644]	Shavit, Y.; Ben-Eliyahu, S.; Zeidel, A.; Beilin, B., Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neu-roimmunomodulation 2004, 11 (4), 255-60.
[645]	Skarvan, K.; Schwinn, W., [Hemodynamic interaction between midazolam and alfentanil in coronary patients]. Anaesthesist 1986, 35 (1), 17-23.
[646]	Stefano, G. B.; Scharrer, B.; Smith, E. M.; Hughes, T. K., Jr.; Magazine, H. I.; Bilfinger, T. V.; Hartman, A. R.; Fricchione, G. L.; Liu, Y.; Makman, M. H., Opioid and opiate immunoregulatory processes. Crit. Rev. Immunol. 1996, 16 (2), 109-44.
[647]	Stefano, G. B.; Rodriguez, M.; Glass, R.; Cesares, F.; Hughes, T. K.; Bilfinger, T. V., Hyperstimulation of leukocytes by plasma from cardiopulmonary bypass patients is diminished by morphine and IL-10 pretreatment. J. Cardiovasc. Surg. (Torino). 1995, 36 (1), 25-30.
[648]	Vermeyen, K. M.; Erpels, F. A.; Beeckman, C. P.; Janssen, L. A.; Adriaensen, H. F., Low-dose sufentanil-isoflurane anaesthesia for coronary artery surgery. Br. J. Anaesth. 1989, 63 (1), 44-50.
[649]	Goto, A.; Kadowaki, T.; Kitagawa, Y., Drosophila hemolectin gene is expressed in embryonic and larval hemocytes and its knock down causes bleeding defects. Dev. Biol. 2003, 264 (2), 582-91.
[650]	Anim-Nyame, N.; Gamble, J.; Sooranna, S. R.; Johnson, M. R.; Sullivan, M. H.; Steer, P. J., Evidence of impaired microvascular function in pre-eclampsia: a non-invasive study. Clin Sci (Lond) 2003, 104 (4), 405-12.
[651]	Bryson, C. L.; Ioannou, G. N.; Rulyak, S. J.; Critchlow, C., Association between gestational diabetes and pregnancy-induced hyperten-sion. Am. J. Epidemiol. 2003, 158 (12), 1148-53.
[652]	Harskamp, R. E.; Zeeman, G. G., Preeclampsia: at risk for remote cardiovascular disease. Am. J. Med. Sci. 2007, 334 (4), 291-5.
[653]	Inglis, T. C.; Stuart, J.; George, A. J.; Davies, A. J., Haemostatic and rheological changes in normal pregnancy and pre-eclampsia. Br. J. Haematol. 1982, 50 (3), 461-5.
[654]	Kabon, B.; Nagele, A.; Reddy, D.; Eagon, C.; Fleshman, J. W.; Sessler, D. I.; Kurz, A., Obesity decreases perioperative tissue oxygenation. Anesthesiology 2004, 100 (2), 274-80.
[655]	Ogawa, T.; Suzuki, Y.; Sayama, S.; Soma, H., Possible relationship between the ratio of Factor VIII complex and placental insufficiency in preeclampsia. Biol. Res. Pregnancy Perinatol. 1983, 4 (4), 155-7.
[656]	Roy, K. K.; Malhotra, N.; Banerjee, K., Recurrent eclampsia in a woman with chronic pyelonephritis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001, 94 (2), 307-8.
[657]	Scholtes, M. C.; Gerretsen, G.; Haak, H. L., The factor VIII ratio in normal and pathological pregnancies. Eur. J. Obstet. Gynecol. Reprod. Biol. 1983, 16 (2), 89-95.
[658]	Thornton, C. A.; Bonnar, J., Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy. Br. J. Obstet. Gynaecol. 1977, 84 (12), 919-23.
[659]	Weiner, C. P.; Brandt, J., Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia. Am. J. Obstet. Gynecol. 1982, 142 (3), 275-81.
[660]	Khatun, S.; Kanayama, N.; Belayet, H. M.; Tokunaga, N.; Sumimoto, K.; Kobayashi, T.; Terao, T., Induction of hypercoagulability condition by chronic localized cold stress in rabbits. Thromb. Haemost. 1999, 81 (3), 449-55.
[661]	Newman, M. G.; Lindsay, M. K.; Graves, W., Cigarette smoking and pre-eclampsia: their association and effects on clinical outcomes. J. Matern. Fetal Med. 2001, 10 (3), 166-70.
[662]	Frank, J. M.; Palomino, N. J., Primary amyloidosis with diffuse splenic infiltration presenting as fulminant pneumococcal sepsis. Am. J. Clin. Pathol. 1987, 87 (3), 405-7.
[663]	Angelov, A., Intracranial venous thrombosis in relation to pregnancy and delivery. Pathol. Res. Pract. 1989, 185 (6), 843-7.
[664]	Angelov, A., Intravascular coagulation in relation to pregnancy and delivery. Zentralbl. Gynakol. 1989, 111 (17), 1169-75.
[665]	Bruhn, H. D.; Bernsmeier, R.; Luck, P.; Zurborn, K. H.; Christophers, E., Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro. Klin. Wochenschr. 1983, 61 (4), 209-11.
[666]	Darmoul, D.; Gratio, V.; Devaud, H.; Lehy, T.; Laburthe, M., Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 2003, 162 (5), 1503-13.
[667]	De Vos, J.; Couderc, G.; Tarte, K.; Jourdan, M.; Requirand, G.; Delteil, M. C.; Rossi, J. F.; Mechti, N.; Klein, B., Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001, 98 (3), 771-80.
[668]	Dvorak, H. F., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315 (26), 1650-9.
[669]	Farber, E., Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res. 1995, 55 (17), 3759-62.
[670]	Klementsen, B.; Jorgensen, L., Mechanisms involved in the early interaction between HeLa cells, platelets and endothelial cells in vitro under the influence of thrombin. Effects of acetylsalicylic acid and Na-salicylate. APMIS 1997, 105 (5), 391-401.
[671]	Poste, G.; Greig, R., On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 1982, 2 (3), 137-76.
[672]	Sporn, M. B., Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res. 1991, 51 (23 Pt 1), 6215-8.
[673]	Versteeg, H. H.; Spek, C. A.; Richel, D. J.; Peppelenbosch, M. P., Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004, 23 (2), 410-7.
[674]	Jin, E.; Fujiwara, M.; Pan, X.; Ghazizadeh, M.; Arai, S.; Ohaki, Y.; Kajiwara, K.; Takemura, T.; Kawanami, O., Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer 2003, 97 (3), 703-13.
[675]	Orbach, H.; Zandman-Goddard, G.; Amital, H.; Barak, V.; Szekanecz, Z.; Szucs, G.; Danko, K.; Nagy, E.; Csepany, T.; Carvalho, J. F.; Doria, A.; Shoenfeld, Y., Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. N. Y. Acad. Sci. 2007, 1109, 385-400.
[676]	Lind, S. E.; Smith, D. B.; Janmey, P. A.; Stossel, T. P., Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am. Rev. Respir. Dis. 1988, 138 (2), 429-34.
[677]	Lind, S. E.; Janmey, P. A., Human plasma gelsolin binds to fibronectin. J. Biol. Chem. 1984, 259 (21), 13262-6.
[678]	Lind, S. E.; Smith, D. B.; Janmey, P. A.; Stossel, T. P., Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J. Clin. Invest. 1986, 78 (3), 736-42.
[679]	Janmey, P. A.; Lind, S. E.; Yin, H. L.; Stossel, T. P., Effects of semi-dilute actin solutions on the mobility of fibrin protofibrils during clot formation. Biochim. Biophys. Acta 1985, 841 (2), 151-8.
[680]	Wada, H.; Wakita, Y.; Nakase, T.; Shimura, M.; Hiyoyama, K.; Nagaya, S.; Deguchi, H.; Mori, Y.; Kaneko, T.; Deguchi, K.; Fujii, J.; Shiku, H., Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am. J. Hematol. 1996, 51 (4), 255-60.
[681]	Wada, H.; Sase, T.; Matsumoto, T.; Kushiya, F.; Sakakura, M.; Mori, Y.; Nishikawa, M.; Ohnishi, K.; Nakatani, K.; Gabazza, E. C.; Shiku, H.; Nobori, T., Increased soluble fibrin in plasma of patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2003, 9 (3), 233-40.
[682]	Bowie, E. J.; Owen, C. A., The clinical pathology of intravascular coagulation. Bibl. Haematol. 1983, (49), 217-24.
[683]	Hardaway, R. M.; Chun, B.; Rutherford, R. B., Histologic evidence of disseminated intravascular coagulation in clinical shock. In Vasc. Dis., 1965; Vol. 2, pp 254-65.
[684]	Hardy, J. F.; de Moerloose, P.; Samama, C. M., The coagulopathy of massive transfusion. Vox Sang. 2005, 89 (3), 123-7.
[685]	Singh, M. V.; Salhan, A. K.; Rawal, S. B.; Tyagi, A. K.; Kumar, N.; Verma, S. S.; Selvamurthy, W., Blood gases, hematology, and renal blood flow during prolonged mountain sojourns at 3500 and 5800 m. Aviat. Space Environ. Med. 2003, 74 (5), 533-6.
[686]	Suzuki, S.; Morishita, S., Hypercoagulability and DIC in high-risk infants. Semin. Thromb. Hemost. 1998, 24 (5), 463-6.
[687]	Ruttmann, T. G.; Montoya-Pelaez, L. F.; James, M. F., The coagulation changes induced by rapid in vivo crystalloid infusion are attenuated when magnesium is kept at the upper limit of normal. Anesth. Analg. 2007, 104 (6), 1475-80, table of contents.
[688]	Chappell, D.; Jacob, M.; Hofmann-Kiefer, K.; Conzen, P.; Rehm, M., A rational approach to perioperative fluid management. Anesthesiology 2008, 109 (4), 723-40.
[689]	Lane, N., Power, Sex, Suicide Mitochondria and the Meaning of Life. Oxford University Press: New York, 2005; p 346.
[690]	Mattick, J. S., The regulatory architecture of the human genome. Asia Pac J Clin Nutr 2004, 13 (Suppl), S14.
[691]	Mattick, J. S., The hidden genetic program of complex organisms. Sci. Am. 2004, 291 (4), 60-7.
[692]	Mattick, J. S., Challenging the dogma: the hidden layer of non-protein-coding RNAs in complex organisms. Bioessays 2003, 25 (10), 930-9.
[693]	Kirschner, M. W.; Gerhart, J. C., The Plausibility of Life: Resolving Darwin's Dilemma. Vail-Ballou Press: 2005.
[694]	Johnson, M. H.; Day, M. L., Egg timers: how is developmental time measured in the early vertebrate embryo? Bioessays 2000, 22 (1), 57-63.
[695]	Pontin, J., A Decade of Genomics. Technol. Rev. 2010, p 1.
[696]	Gibbs, W. W., Untangling the roots of cancer. Sci. Am. 2003, 289 (1), 56-65.
[697]	Kuhn, T. S., The Structure of Scientific Revolutions. University of Chicago Press: 1996.